

National Cancer Control Programme



Cancer Incidence Data
Sri Lanka
2009

Cancer Incidence Data

Sri Lanka 2009



National Cancer Control Programme
555, Elvitigala Mawatha
Colombo 5
Sri Lanka

Cancer Surveillance Team

Dr. Eshani Fernando

Dr. Suraj Perera

Dr. Prasanna Jayasekera

Dr. K.G. Nirmala Jayanthi

Dr. Kamal Seneviratne

Dr. Asanga Hemaratna

Dr. Pushpika Samarakoon

Dr. Ruvanmalie Liyanagama

Dr. Ranjith Gunasena

Dr. Dushan Baddage

Sr. Chamila Peiris

ISBN: 978-955-0505-74-6

National Cancer Control Programme - 2015

11th Publication

Printed by P&G Printers (Pvt) Ltd (2 447722)

Contributors

Data collection

Dr. K.G. Nirrmala Jayanthi

Dr. P.R.T.D. Peramuna

Dr. Asanga Hemaratna

Dr. W.T.D.N. Weerasingha

Dr. Pushpika Samarakoon

Dr. Gayani Isanka

Dr. Methsala Gunawardana

Dr. S.A. Himala Dilani Wijekoon

Dr. A.W. Kaushika Dilrukshi

Dr. R.W. Keshika

Dr. B.G. Anushka Ratnamali

Dr. D.M.H.N. Disanayake

Dr. W.A. I.W. Gunathilake

Data Coding

Dr. K.G. Nirmala Jayanthi

Dr. Asanga Hemaratna

Dr. Pushpika Samarakoon

Dr. Ruvanmalie Liyanagama

Sr. Chamila Peiris

Verification

Dr. K.G. Nirmala Jayanthi, Dr. Pushpika Samarakoon & Dr. Eshani Fernando

Data entry

Ms. Nimesha Prasadi

Ms. Prabashi Gayanthika

Statistical Analysis and Report Writing

Dr. Eshani Fernando

Support staff

Mr. Saman Kumara Mahalekam

Ms. Thushari Dhammika

Mr. U.K. Sumanasiri

Mr. Siripala Perera

Message from Director General of Health Services



It is with pleasure that I send a message for the publication, “Cancer Incidence Data Sri Lanka 2009” which is the 11th publication in the series.

Cancer surveillance is a key strategy for cancer control in any country. Periodic publication of incidence data on cancer is very useful in resource planning and allocation as well as monitoring and evaluation of the cancer control activities in Sri Lanka.

The series of cancer incidence data publications will be very useful for researchers and for epidemiologists to analyse trends related to main cancers in Sri Lanka.

Finally, I wish to extend my sincere appreciation to the World Health Organisation for supporting the cancer surveillance activities in Sri Lanka and to the staff of the National Cancer Control Programme for their effort in publishing this document.

Dr. Palitha Mahipala

Director General of Health Services

Message from Deputy Director General of Medical Services



I am pleased to note that cancer incidence data are collected from many different sources such as pathology laboratories where most cancers are diagnosed and Oral & Maxillo-Facial Units where some of the oral cancers are first managed in addition to the main cancer treatment centres of the country.

Release of this report has become a routine of the National Cancer Control Programme and this surveillance mechanism is vital and very important for monitoring of the programme. This will invariably lead to improvement of cancer control in many ways in Sri Lanka.

I wish to thank the dedicated work of the Director and staff of the National Cancer Control Programme for publication of this report.

Dr. Lakshmi Somathunga

Deputy Director General of Medical Services

Forward



It is with pride that I present the cancer incidence data of Sri Lanka for the year 2009 within 6 months of publication of 2008 data. This would not have been possible except for the dedication and hard work done by the cancer surveillance team of the National Cancer Control Programme. I wish to express my sincere appreciation and thank the entire team for their effort.

There is a severe backlog in publishing cancer incidence data due to many reasons such as limited resource availability for data collection and entry. The plan of the National Cancer Control Programme is to publish a minimum of two publications per year until the backlog gets cleared. It is also expected to publish an interim report for the year 2014 as early as possible toward the beginning of next year.

I am thankful to the higher officials of the Ministry of Health for taking a keen interest in fulfilling the manpower requirement for producing data of national importance for planning, monitoring and evaluation of cancer control in Sri Lanka.

Dr Eshani Fernando

Acting Director

National Cancer Control Programme

Table of Contents

	Page No.
Cancer surveillance team	ii
Contributors	iii
Message from the Director General Of Health Services	v
Message from the Deputy Director General of Medical Services	vii
Forward	ix
List of tables	vii
List of figures	xi
Executive Summary	1
Introduction	2
Methodology	2
Data tables and Graphs	4
List of references	69
Appendix I- Statistical Terminology	70

List of Tables

Table No.	Description	Page No.
01	General Population: Sex Distribution	4
02	Denominators used for calculation of the Cancer Registry	4
03	Statistics on doctors, hospitals and hospital beds	5
04	Cancer mortality data, 2000-2009	5
05	Cancer mortality data by sex, 2001-2009	5
06	Cancer Incidence in Sri Lanka -2009	6
07	Overall Cancer Incidence, 2009 by age and sex	7
08	Leading cancer sites- 2009	8
09	Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years) of leading cancer sites- 2009	9
10	Cancer cases by age group-Male 2009	16
11	Cancer cases by age group-Female 2009	18
12	Cancer cases by ethnicity, sex and sub-site, 2009	20
13	Cancer incidence by sub-site and histological type 2009 <i>Incidence data by major site 2009</i>	22
14	Lip, oral cavity and pharynx	45
15	Lip and anterior part of oral cavity	47
16	Posterior part of oral cavity and pharynx	48
17	Trachea, bronchus and lungs	49
18	Larynx	50
19	Oesophagus	51
20	Stomach	52
21	Colon and rectum	53
22	Colon	54
23	Rectum, anal canal and anus	55

Table No.	Description	Page No.
24	Breast	56
25	Cervix uteri	57
26	Ovary	58
27	Skin	59
28	Brain	60
29	Thyroid gland	61
30	Urinary Bladder	62
31	Hematopoietic and reticuloendothelial system	63
32	Prostate gland	64
33	Basis of diagnosis of cancer patients 2007	66
34	Cancer Treatment 2007	67

List of Figures

Figure No.	Description	Page No.
01	General population of Sri Lanka by 5-year age groups- 2009	4
02	Age standardized death rates, 2001-2009	6
03	Cancer Incidence Rates 2009	6
04	Age Specific Cancer Incidence Rates 2009	7
05	Leading cancer sites 2009	10
06	Leading cancers by age group	11
07	Age specific rates-Lip, oral cavity and pharynx	46
08	Age specific rates-Trachea, bronchus and lungs	49
09	Age specific rates- Larynx	50
10	Age specific rates- Oesophagus	51
11	Age specific rates- Stomach	52
12	Age specific rates- Colon and rectum	53
13	Age specific rates- Colon	54
14	Age specific rates- Rectum, anal canal and anus	55
15	Age specific rates- Breast	56
16	Age specific rates- Cervix uteri	57
17	Age specific rates- Ovary	58
18	Age specific rates- Skin	59
19	Age specific rates- Brain	60
20	Age specific rates- Thyroid gland	61
21	Age specific rates- Urinary bladder	62
22	Age specific rates- Hematopoietic and reticuloendothelial system	63
23	Age specific rates- Prostate gland	64
24	Stage at diagnosis- Cervical cancer	65
25	Stage at diagnosis- Breast cancer	65
26	Stage at diagnosis- oral cancer	65
27	Basis of diagnosis	66
28	Basis of diagnosis by major categories	66
29	Percentage of patients who received different types of treatment	68

Executive summary

The 2009 publication of cancer incidence data of Sri Lanka is the 11th volume in the series of publications. This publication presents the cancer incidence data collected from 42 sources namely all nine cancer treatment centres in the country, 18 maxillo-facial surgery units, and 15 pathology laboratories. The increase in the number of cases from 2008 to 2009 is 377. A substantial increase in the age standardised rates (ASR) has been observed only for lip, oral cavity and pharyngeal cancers from 2008 to 2009. It has increased by 0.8 per 100,000 population. For other cancer sites the increase observed was not significant.

The crude incidence rate for all cancers was 82.6 per 100,000 population and the age standardised rate, 87.5 per 100,000 population. The female cancer with the highest incidence was cancers of the breast (CR=22.2 and ASR =22.3). The 'lip, oral cavity and pharyngeal cancers remained the leading cancer among males with a CR of 17.5 and an ASR of 19.4. It was observed that the top ten cancers had remained the same for males but for female cancers, Leukaemias have replaced Lymphomas. The five leading cancers among the males were, 'lip, oral cavity and the pharynx', 'trachea, bronchus and lung', oesophagus, 'colon and rectum', and lymphoma. The five leading cancer sites among females were breast, cervix uteri, thyroid gland, ovary and oesophagus.

The life time risk of developing any type of cancer (calculated for 0-74 years) in the population was one in every 10 persons for both males and females. In the case of breast cancer, one in every 40 females have a risk of developing a breast cancer during their lifetime and one in every 42 males have a risk of developing a cancer of the lip, oral cavity or the pharynx.

Treatment received by cancer patients diagnosed in 2009 was as follows. Out of all patients, 35% had received surgery, 45% had received radiotherapy, 48% chemotherapy and 8% hormone therapy whereas 2.3% had received only symptomatic treatment.

The percentage of microscopically confirmed cases was 94.1% out of which 86.7% were diagnosed by histology of the primary site.

According to the data of Department of Census and Statistics, eleven thousand two hundred and eighty six (11,286) deaths have occurred due to neoplasms in 2009 of which 54% had been males. The crude death rate for the year had been 55.2 per 100,000 population and the ASR, 59.4 per 100,000 population. The proportionate mortality due to neoplasm was 8.8% which was as same as for 2006.

Introduction

The first published data on cancer incidence in Sri Lanka was for the year 1985. Annual publication of data had stopped in 1987 due to logistic reasons and five-yearly publications had been done from 1990 to 2005. Thereafter the annual publication of cancer incidence data was recommenced. Data collected only from the cancer treatment centres had been published till 2005. In the publications from 2006, data from oral and maxillo facial units and pathology labs have been incorporated. The mortality data on cancer published here is from the data received from the Registrar General's Department of Sri Lanka. The present publication presents cancer incidence data of 2009.

Methodology

Cancer incidence data of 2009 represents data collected from all 9 (nine) cancer treatment centres in the country, 17 (seventeen) Oral & Maxillofacial Surgery Units and 15 (fifteen) Pathology laboratories of government hospitals. The data sources are given below.

Cancer Treatment Centres:

National Cancer Institute, Maharagama

Teaching Hospitals, Kandy, Karapitiya, Jaffna, Anuradapura and Batticaloa

Provincial General Hospitals Badulla, Kurunegala and Ratnapura

Oral & Maxillo- Facial Surgery Units in:

Dental Institute, Colombo

Teaching Hospitals, Anuradhapura, Colombo South, Kandy, Karapitiya and Ragama

Provincial General Hospital, Badulla

District General Hospitals, Chillaw, Gampaha, Kalutara, Matale, Matara, Polonnaruwa and Kegalle

Base Hospital, Avissawella, Kuliyaipitiya and Panadura

Pathology Laboratories in:

National Hospital Sri Lanka

De Soysa Hospital for Women

Castle Street Hospital for Women

Lady Ridgeway Hospital

Medical Research Institute

Faculty of Medicine, Karapitiya

National Eye Hospital

Faculty of Dental Sciences, Peradeniya

Teaching Hospitals, Colombo North, Kandy and Welisara (Chest)

District General Hospitals, Kalutara and Negombo

Base Hospitals, Wathupitiwela and Panadura

Cancer incidence data from, newly included cancer treatment centres, Batticaloa and Ratnapura were collected by registry staff. Data of the Jaffna cancer treatment centre were collected by the centre and sent directly to the registry. This year also collection of cancer incidence data from other six cancer treatment centres was done

actively by pre-intern medical graduates who had been specifically trained to perform this task by registry staff. Patients' clinic record files were used to extract relevant data for the cancer registry. In places where pre-intern medical graduates were used, data retrieval was done under close supervision by registry staff initially and later, a random sample was checked to improve reliability of data. Data quality checks were made during coding of data, while data entering to CanReg 5 software and at the basic analysis level. The clinic record numbers of all data sheets suspected with errors were noted and the relevant patient files were re-examined and necessary corrections were done to the data sheets.

Data from the Oral & Maxillofacial Surgery Units and the Pathology laboratories were collected passively using data collection formats supplied by the NCCP to these institutions.

The date of first histological or cytological confirmation or the date of confirmation by clinical investigation was taken as the date of incidence. In instances this information was not available; date of admission to the hospital due to the malignancy was taken as the incidence date.

International Classification of Disease for Oncology (ICDO-3) was used for topographical and morphological coding. This cleaned data was then fed to the computer using CanReg5 package by two data entry operators who had been trained by the registry staff. Due to the increased number of data capturing points in 2008, especially the pathology laboratories, duplicate searching was a laborious process. In addition to the duplicate search facility of CanReg5, excel sheets were also utilised to identify duplicate entries which were not identified by the Canreg5 software due to minor changes in spelling of names, addresses etc. All multiple entries due to patients being registered in more than one treatment centre were identified and removed from the database using the duplicate searching mechanisms in the software by matching basic information of the patient, demographic variables, topography and morphology.

Cases under behaviour code '3' (Malignant primary site) only was included in the analysis.




Figure 01: General population in Sri Lanka by 5-year age groups

Table 01: General population: Sex Distribution

Population ('000)	Year								
	2001	2002	2003	2004	2005	2006	2007	2008	2009
Male	9,359	9,350	9,475	9,678	9,782	9,889	9,956	10,060	10,148
Female	9,438	9,571	9,698	9,757	9,862	9,969	10,083	10,186	10,302
Sex Ratio ¹	99.2	97.7	97.7	99.2	99.2	99.2	98.7	98.8	98.5

¹ Number of males per 100 females

Source: Department of Census and Statistics

Table 02: Denominators used for calculations in the Cancer Registry

Population ('000)	Year 2009
Male	10,148
Female	10,302
Total	20,450

Source: Department of Census and Statistics

Table 03: Statistics on doctors, hospitals and hospital beds
(Government Institutions)

	Year							
	2001	2002	2003	2005	2006	2007	2008	2009
Doctors (MOO+DSS)	9,135	10,157	NA	11,152	11,460	12,337	13,337	
Population per doctor	2,058	1,863	NA	1,764	1,733	1,625	1518	1491
Hospitals	569	576	607	608	614	615	647	642
Beds	57,946	59,144	59,262	61,594	67,024	68,694	67,942	70,842
Beds per 1000 population	3.1	3.1	3.1	3.2	3.4	3.4	3.4	4.0

NA- Not Available

Source: Medical Statistics Unit, Ministry of Health

Table 04: Cancer mortality data, 2000-2009

Year	Population at risk ('000)	Cancer deaths	Crude annual cancer death rate per 100,000	Proportionate mortality rate
2000	19,102	7,842	41.1	6.7
2001	18,797	8,063	42.9	7.1
2002	18,921	7,986	42.2	7.1
2003	19,173	8,396	43.8	7.3
2004	19,435	9,127	47.0	7.9
2005	19,644	9,403	47.9	7.1
2006	19,858	10,386	52.3	8.8
2009	20,450	11,286	55.2	8.8

Source: Registrar General's Department

Table 05: Cancer mortality data by sex, 2001-2009

Year	Number of cancer deaths		Crude Annual Death Rate per 100,000 population		Age Standardised Death Rate per 100,000 population	
	Male	Female	Male	Female	Male	Female
2001	4375	3688	46.7	39.1	52.1	39.9
2002	4350	3636	46.5	37.9	51.2	38.6
2003	4614	3782	48.7	38.9	53.6	39.6
2004	4942	4185	51.1	42.9	57.3	44.0
2005	4983	4420	50.9	44.8	57.0	45.8
2006	5644	4742	57.1	47.6	63.6	48.7
2009	6105	5181	60.2	50.3	67.6	52.0

Source: Registrar General's Department




Figure 02: Age standardised death rates – 2001-2009

Table 06: Cancer Incidence in Sri Lanka- 2009

Sex	Number	%	CR	ASR
Male	7858	46.5	77.4	86.4
Female	9030	53.5	87.7	89.1
Total	16888	100.0	82.6	87.5




Figure 03: Cancer Incidence Rates- 2009

Table 07: Overall Cancer Incidence, 2009 by age and sex

Age group	Male			Female			Total		
	Cases	Population	Incidence	Cases	Population	Incidence	Cases	Population	Incidence
Not Known	33			19			52		
0-4	113	883	12.8	94	855	11.0	207	1,738	11.9
5-9	85	913	9.3	57	886	6.4	142	1,799	7.9
10-14	67	934	7.2	42	907	4.6	109	1,841	5.9
15-19	87	1,005	8.7	78	979	8.0	165	1,984	8.3
20-24	106	964	11.0	118	958	12.3	224	1,922	11.7
25-29	117	792	14.8	211	824	25.6	328	1,616	20.3
30-34	124	771	16.1	308	793	38.8	432	1,564	27.6
35-39	204	751	27.2	453	773	58.6	657	1,524	43.1
40-44	368	700	52.6	629	711	88.5	997	1,411	70.7
45-49	635	609	104.3	987	628	157.2	1622	1,237	131.1
50-54	855	548	156.0	1202	567	212.0	2057	1,115	184.5
55-59	1050	386	272.0	1322	422	313.3	2372	808	293.6
60-64	1171	294	398.3	1147	309	371.2	2318	603	384.4
65-69	1078	223	483.4	948	257	368.9	2026	480	422.1
70-74	863	172	501.7	701	196	357.7	1564	368	425.0
75+	902	203	444.3	714	237	301.3	1616	440	367.3
Total	7858	10,148	77.4	9,030	10,302	87.7	16,888	20450	82.6


**Figure 04: Age Specific Cancer Incidence Rates- 2009**

Table 08: Leading cancer sites-2009

Rank	Male				Female				Total			
	Site	No.	CR	ASR	Site	No.	CR	ASR	Site	No.	CR	ASR
1	Lip, oral cavity and pharynx	1773	17.5	19.4	Breast	2293	22.3	22.2	Breast	2350	11.5	11.8
2	Trachea, bronchus and lungs	875	8.6	10.0	Cervix uteri	879	8.5	8.7	Lip, oral cavity and pharynx	2293	11.2	12.0
3	Oesophagus	656	6.5	7.3	Thyroid gland	816	7.9	7.4	Cervix uteri	879	8.5	8.7
4	Colon and rectum	489	4.8	5.8	Ovary	698	6.8	6.8	Ovary	698	6.8	6.8
5	Lymphoma	408	4.0	4.3	Oesophagus	608	5.91	6.2	Oesophagus	1264	6.2	6.8
6	Unknown primary site	404	4.0	4.5	Lip, oral cavity and pharynx	520	5.0	5.2	Trachea, bronchus and lungs	1099	5.4	6.0
7	Larynx	393	3.9	4.4	Colon and rectum	517	5.0	5.5	Colon and rectum	1067	5.2	5.6
8	Prostate gland	381	3.8	4.4	Uterus	397	3.9	4.1	Thyroid gland	996	4.9	4.7
9	Leukaemia	378	3.7	4.0	Leukaemia	310	3.0	3.2	Prostate gland	381	3.8	4.4
10	Bladder	260	2.6	2.9	Unknown primary site	289	2.8	2.9	Unknown primary site	693	3.4	3.7
	All sites	7858	77.4	86.4	All sites	9030	87.7	89.1	All sites	16888	82.6	87.5

CR: Crude rate per 100,000 population

ASR: Age standardized rate per 100,000 world population

The cumulative incidence rate given in Table 07 is a summary measure of the age specific incidence rates from 0-74 years. It is the summation of values of all the age specific incidence rates multiplied by 5 (as incidence rates were calculated for 5 year age groups) expressed per 100 persons in the population.

The life time risk of developing the leading cancers is also given in Table 07. The life time risk is given as a percentage, the risk of developing a particular cancer per 100 persons in the population as well as risk of developing a particular cancer given as number of persons per new case developed. One in every 10 males and females will develop cancer during their lifetime (0-74 years).

**Table 09: Cumulative Incidence Rate (%) and Lifetime Risk (0-74 years)
of leading cancer sites- 2009**

ICD O Code	Site	Male		Female		Total	
		Cumulative Rate	Lifetime Risk 1% (n) ²	Cumulative Rate	Lifetime Risk % (n)	Cumulative Rate	Lifetime Risk % (n)
C00-C06, C09-C14	Lip, oral cavity and pharynx	2.388	2.36 (42)	0.629	0.627 (159)	1.47	1.459 (69)
C15	Oesophagus	0.922	0.917 (109)	0.816	0.812 (123)	0.867	0.863 (116)
C16	Stomach	0.316	0.316 (316)	0.115	0.115 (870)	0.0211	0.210 (476)
C18-C20	Colon and rectum	0.711	0.708 (141)	0.657	0.655 (153)	0.681	0.679 (147)
C32	Larynx	0.586	0.584 (171)	0.059	0.059 (1695)	0.310	0.309 (324)
C33-C34	Trachea, bronchus and lungs	1.328	1.319 (76)	0.300	0.299 (334)	0.790	0.787 (127)
C50	Breast	0.077	0.077 (1298)	2.512	2.480 (40)	1.338	1.329 (75)
C53	Cervix uteri	-	-	1.028	1.023 (98)	-	-
C54-C55	Uterus	-	-	0.498	0.497 (201)	-	-
C56	Ovary	-	-	0.772	0.769 (130)	-	-
C61	Prostate gland	0.579	0.577 (173)	-	-	-	-
C73	Thyroid gland	0.187	0.187 (534)	0.711	0.709 (141)	0.456	0.455 (220)
C80	Unknown primary site	0.563	0.562 (178)	0.366	0.365 (274)	0.459	0.458 (218)
	Lymphoma	0.454	0.453 (221)	0.274	0.273 (366)	0.361	0.36 (278)
	Leukaemia	0.317	0.316 (316)	0.266	0.266 (376)	0.291	0.291 (344)
	All sites	10.376	9.856 (10)	10.17	9.67 (10)	10.24	9.733 (10)

1- %- Life time risk as a percentage (per 100 persons)

2- (n)- Number of population per one new case detected





Figure 05: Leading Cancer Sites 2009





Figure 06A: Leading cancers by age group: 0-14 years





Figure 06B: Leading cancers by age group: 15-34 years





Figure 06C: Leading cancers by age group: 35-49 years





Figure 06D: Leading cancers by age group: 50-64 years





Figure 06E: Leading cancers by age group: 65 years & above

Table 10: Cancer cases by age group-Male 2009

ICD O Code and Site	Age Group																Total
	No. of cases	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	
C00 Lip	0	0	0	0	0	0	0	0	0	3	3	3	13	6	5	11	44
C01 Base of tongue	0	0	0	0	0	0	0	1	5	7	12	18	16	15	11	14	110
C02 Other and unspecified parts of tongue	1	0	0	0	0	1	0	1	12	26	50	54	69	57	44	26	364
C03 Gum	0	0	0	0	0	0	0	0	1	8	6	15	14	11	8	15	92
C04 Floor of mouth	0	0	0	0	0	0	0	0	3	3	11	23	9	15	12	12	93
C05 Palate	1	0	0	0	1	0	0	0	5	9	14	17	16	22	18	13	134
C06 Other and unspecified parts of mouth	2	0	0	0	2	0	2	0	4	20	44	55	68	69	67	64	474
C07 Parotid gland	0	0	0	1	1	3	0	0	3	5	6	0	2	4	3	3	35
C08 Other and unspecified major salivary glands	0	0	0	0	0	1	0	1	1	1	3	1	3	1	2	2	17
C09 Tonsil	0	0	0	0	1	0	1	2	2	8	17	6	23	15	9	7	98
C10 Oropharynx	0	0	0	0	0	0	0	0	0	3	5	11	19	8	13	5	70
C11 Nasopharynx	0	0	0	3	2	0	3	0	1	4	4	5	3	5	4	4	40
C12 Pyriform sinus	1	0	0	0	0	0	0	2	2	5	18	21	23	25	27	19	162
C13 Hypopharynx	0	0	0	0	0	0	0	0	1	1	2	1	7	4	6	6	29
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	0	0	0	1	0	6	8	6	13	12	7	5	63
C15 Oesophagus	1	0	0	0	0	0	1	5	6	23	48	95	110	109	107	70	656
C16 Stomach	0	0	0	0	0	0	0	0	2	9	20	33	34	32	43	23	222
C17 Small intestine	0	1	0	0	0	0	0	0	1	1	2	2	3	5	3	2	21
C18 Colon	2	1	0	0	0	0	3	8	7	19	21	26	22	41	24	22	218
C19 Rectosigmoid junction	0	0	0	0	0	0	0	0	0	1	5	1	6	5	9	2	32
C20 Rectum	0	0	0	0	0	1	2	3	7	5	25	23	46	40	51	29	271
C21 Anus and anal canal	0	0	0	0	0	0	1	0	1	2	0	2	3	2	5	2	22
C22 Liver and intrahepatic bile ducts	2	1	1	3	1	1	1	2	1	4	3	9	11	28	23	15	119
C23 Gallbladder	0	0	0	0	0	0	0	0	1	1	0	2	1	1	2	0	8
C24 Other and unspecified parts of biliary tract	1	1	0	0	1	0	0	1	2	4	4	2	4	4	4	3	32
C25 Pancreas	1	0	0	0	0	0	1	0	2	6	8	11	8	9	4	4	60
C26 Other and ill-defined digestive organs	0	0	0	0	0	0	0	0	0	0	0	0	3	0	2	0	5
C30 Nasal cavity and middle ear	0	1	0	0	0	0	2	0	1	1	1	1	1	1	2	2	13
C31 Accessory sinuses	0	0	1	0	0	0	0	0	1	0	3	3	5	0	2	3	20
C32 Larynx	0	0	0	0	0	0	2	0	4	10	26	55	51	66	66	61	393
C33 Trachea	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C34 Bronchus and lung	5	0	0	0	2	2	3	5	8	39	54	98	137	193	136	117	874
C37 Thymus	0	0	0	0	0	2	0	1	1	2	0	0	0	2	1	0	9
C38 Heart, mediastinum and pleura	0	2	1	0	2	5	2	0	1	2	2	0	1	0	1	1	22
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	0	0	0	0	0	0	0	0	0	1	2	1	2	4	6	2	18
C40 Bones, joints and articular cartilage of limbs	0	0	4	4	11	8	4	0	0	0	1	0	1	0	0	0	34
C41 Bones, joints and articular cartilage of other and unspecified sites	0	1	2	2	2	3	2	0	0	0	2	1	3	2	1	0	22

ICD O Code and Site	Age Group																	
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Total
C42 Hematopoietic and reticuloendothelial systems	2	52	40	27	24	23	21	17	25	24	32	38	50	46	48	29	46	544
C44 Skin	1	1	1	1	2	5	5	6	6	8	20	23	19	22	22	26	30	198
C47 Peripheral nerves and autonomic nervous system	0	1	0	0	1	1	0	1	2	1	0	1	3	0	0	0	1	12
C48 Retroperitoneum and peritoneum	0	0	0	0	0	0	1	1	0	1	1	0	1	1	0	2	0	8
C49 Connective, subcutaneous and other soft tissues	0	3	3	4	1	1	2	4	2	5	8	5	8	7	7	7	6	73
C50 Breast	1	0	0	0	0	0	1	1	1	4	7	8	4	6	9	8	7	57
C60 Penis	0	0	0	0	0	0	1	4	2	5	7	15	13	10	10	9	12	88
C61 Prostate gland	4	0	0	1	0	0	1	0	0	2	2	14	14	55	75	97	116	381
C62 Testis	0	3	1	0	4	7	11	5	6	4	4	0	2	1	1	0	0	49
C63 Other and unspecified male genital organs	0	0	0	0	0	0	0	0	0	0	0	2	3	2	1	0	2	10
C64 Kidney	2	8	1	1	0	1	1	1	3	2	13	16	14	20	11	7	12	113
C66 Ureter	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	2
C67 Bladder	3	0	0	0	0	1	2	2	4	14	9	23	38	34	47	36	47	260
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
C69 Eye and adnexa	0	15	3	0	3	1	0	1	0	1	0	2	1	1	1	0	2	31
C70 Meninges	0	0	0	0	0	0	1	1	1	1	3	0	0	1	0	0	0	8
C71 Brain	1	9	10	6	8	5	5	12	14	11	13	12	15	13	5	7	3	149
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	0	1	0	1	0	0	0	0	0	1	0	0	0	0	0	0	3
C73 Thyroid gland	0	0	2	2	5	12	15	10	28	15	11	14	17	18	11	11	9	180
C74 Adrenal gland	0	4	5	0	0	0	1	0	0	2	0	0	1	1	1	1	0	16
C75 Other endocrine glands and related structures	0	0	0	0	1	1	0	1	0	0	0	0	0	0	0	0	0	3
C76 Other and ill-defined sites	0	5	0	0	1	1	0	0	0	1	2	4	3	2	4	2	1	26
C77 Lymph nodes	1	4	9	12	9	17	14	17	19	13	33	35	38	48	34	18	24	345
C80 Unknown primary site	1	0	0	0	1	3	5	7	5	16	39	42	66	63	62	47	47	404
Total	33	113	85	67	87	106	117	124	204	368	635	855	1050	1171	1078	863	902	7858

Table 11: Cancer cases by age group-Female 2009

ICD O Code and Site	Age Group																	Total
	Not Kn	0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C00 Lip	0	0	0	0	0	0	0	0	0	0	2	4	2	5	2	2	2	19
C01 Base of tongue	0	0	0	0	0	0	0	0	2	0	0	0	2	2	4	3	0	13
C02 Other and unspecified parts of tongue	2	0	0	0	0	0	0	2	1	5	5	9	6	13	14	12	15	84
C03 Gum	0	0	0	0	0	0	0	1	0	1	4	8	13	5	11	3	14	60
C04 Floor of mouth	0	0	0	0	0	0	0	0	0	2	1	1	1	3	2	1	1	12
C05 Palate	0	0	0	0	0	0	0	0	2	2	3	1	2	5	4	1	11	31
C06 Other and unspecified parts of mouth	1	0	0	1	1	0	0	0	1	3	12	12	34	27	34	30	42	198
C07 Parotid gland	0	0	0	3	2	0	0	3	3	4	4	4	3	2	1	1	6	36
C08 Other and unspecified major salivary glands	0	0	0	0	0	0	1	0	1	0	2	1	1	3	3	2	1	15
C09 Tonsil	0	0	0	0	0	1	1	0	1	0	2	3	1	2	1	0	2	14
C10 Oropharynx	0	0	0	0	0	0	0	0	0	0	2	2	3	0	3	1	0	11
C11 Nasopharynx	0	0	0	0	0	0	0	0	2	1	0	2	3	1	2	0	1	12
C12 Pyriform sinus	0	0	0	0	0	0	0	0	0	0	2	2	4	4	4	3	2	21
C13 Hypopharynx	0	0	0	0	0	1	0	0	0	2	3	5	4	3	5	0	5	28
C14 Other and ill-defined sites in lip, oral cavity and pharynx	0	0	0	0	0	0	0	0	0	1	3	3	2	2	1	4	1	17
C15 Oesophagus	0	0	0	0	0	2	1	5	6	14	30	75	88	94	111	92	90	608
C16 Stomach	0	0	0	0	0	0	1	0	2	2	8	13	20	15	8	12	11	92
C17 Small intestine	0	0	0	0	0	0	1	1	0	3	1	1	1	3	0	2	0	13
C18 Colon	1	0	0	0	0	1	4	8	7	11	19	34	36	35	34	25	15	230
C19 Rectosigmoid junction	0	0	0	0	0	1	0	2	0	1	5	4	5	6	1	3	1	29
C20 Rectum	0	0	0	0	0	1	3	4	5	16	25	37	36	46	29	32	53	287
C21 Anus and anal canal	0	0	0	0	0	0	0	0	0	0	2	3	0	2	2	2	5	16
C22 Liver and intrahepatic bile ducts	0	11	2	1	0	0	1	1	2	1	1	3	4	10	6	0	2	45
C23 Gallbladder	0	0	0	0	0	0	1	2	0	3	2	3	6	2	3	4	4	30
C24 Other and unspecified parts of biliary tract	1	0	0	0	0	0	0	0	0	2	5	7	4	5	1	1	3	29
C25 Pancreas	1	0	0	0	0	0	1	1	4	1	3	6	7	5	6	3	2	40
C26 Other and ill-defined digestive organs	0	1	1	0	0	0	0	0	1	0	1	0	2	1	1	0	0	8
C30 Nasal cavity and middle ear	0	0	0	0	0	0	0	2	1	0	0	1	3	4	1	1	0	13
C31 Accessory sinuses	0	0	0	0	0	0	0	0	1	0	0	3	0	2	3	2	1	12
C32 Larynx	0	0	0	0	0	0	0	1	0	5	1	6	4	8	7	7	2	41
C33 Trachea	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C34 Bronchus and lung	1	1	0	0	2	0	4	2	5	8	15	20	31	37	43	29	25	223
C37 Thymus	0	0	0	0	0	0	0	2	1	1	2	0	3	1	1	2	0	13
C38 Heart, mediastinum and pleura	0	1	0	0	0	1	0	0	2	1	1	1	0	0	0	0	1	8
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	1	0	0	0	0	0	1	0	0	0	0	2	1	3	1	1	2	12
C40 Bones, joints and articular cartilage of limbs	0	0	1	4	7	3	3	1	1	0	0	2	2	2	0	0	0	26

ICD O Code and Site	Not Kn	Age Group																Total
		0-4	5-9	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	
C41 Bones, joints and articular cartilage of other and unspecified sites	0	1	4	1	4	0	2	0	0	2	1	1	2	0	2	2	0	22
C42 Hematopoietic and reticuloendothelial systems	0	42	20	14	16	6	14	16	22	18	47	53	56	44	47	29	37	481
C44 Skin	1	0	1	1	1	0	0	2	5	11	6	8	13	18	12	23	17	119
C47 Peripheral nerves and autonomic nervous system	0	1	1	0	2	0	0	0	0	1	1	1	1	0	0	0	0	8
C48 Retroperitoneum and peritoneum	0	0	2	1	2	0	0	1	0	2	1	1	1	1	2	1	2	17
C49 Connective, subcutaneous and other soft tissues	0	2	2	1	2	4	1	7	2	7	9	7	10	4	8	3	7	76
C50 Breast	6	0	0	0	0	7	18	74	149	239	366	364	398	267	191	117	97	2293
C51 Vulva	0	0	0	0	0	0	0	0	0	1	6	2	3	3	5	8	8	36
C52 Vagina	0	0	0	0	0	0	0	1	0	0	5	3	6	7	2	3	4	31
C53 Cervix uteri	0	0	0	0	0	1	2	10	38	57	128	137	155	121	99	63	68	879
C54 Corpus uteri	1	0	0	0	0	0	2	1	6	17	28	50	62	67	48	26	19	327
C55 Uterus, NOS	0	0	0	0	0	0	2	0	2	7	8	17	13	10	5	1	5	70
C56 Ovary	1	1	1	2	8	10	23	16	27	50	68	133	119	94	63	38	44	698
C57 Other and unspecified female genital organs	0	0	0	0	0	0	0	0	1	2	2	2	1	0	1	0	1	10
C58 Placenta	0	0	0	0	1	4	4	2	1	2	1	0	0	0	0	0	0	15
C64 Kidney	0	1	0	0	1	3	1	1	1	4	5	6	4	7	5	4	3	46
C65 Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	2
C66 Ureter	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	1
C67 Bladder	0	2	0	0	0	1	0	1	0	1	1	3	3	10	10	8	11	51
C69 Eye and adnexa	0	11	0	0	0	0	0	0	1	0	2	1	2	0	1	0	2	20
C70 Meninges	0	0	0	0	0	0	0	0	1	1	2	1	0	0	1	1	0	7
C71 Brain	0	6	9	6	3	3	7	11	6	2	15	9	8	7	6	7	1	106
C72 Spinal cord, cranial nerves and other parts of central nervous system	0	1	0	2	1	1	1	0	0	1	1	2	0	1	0	1	0	12
C73 Thyroid gland	0	0	3	4	18	53	98	109	119	83	76	64	65	53	30	27	14	816
C74 Adrenal gland	0	1	1	0	0	0	1	1	1	1	1	0	0	1	0	0	0	8
C75 Other endocrine glands and related structures	0	0	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	2
C76 Other and ill-defined sites	0	9	3	0	1	1	0	1	0	2	3	0	0	4	3	1	2	30
C77 Lymph nodes	0	1	5	0	6	12	10	12	13	14	14	23	28	19	14	22	18	211
C80 Unknown primary site	2	1	0	0	0	1	2	4	7	13	24	36	38	50	43	34	34	289
Total	19	94	57	42	78	118	211	308	453	629	987	1202	1322	1147	948	701	714	9030

Table 12: Cancer cases by ethnicity, sex and sub-site, 2009

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C00 Lip	44	19	29	10	2	5	3	2	0	0	10	2
C01 Base of tongue	110	13	87	9	10	3	6	0	1	0	6	1
C02 Other and unspecified parts of tongue	364	84	256	54	36	15	9	6	0	0	63	9
C03 Gum	92	60	66	26	5	17	6	5	0	0	15	12
C04 Floor of mouth	93	12	63	4	13	3	3	1	0	0	14	4
C05 Palate	134	31	89	16	19	6	6	0	1	0	19	9
C06 Other and unspecified parts of mouth	474	198	308	80	51	54	10	12	0	1	105	51
C07 Parotid gland	35	36	29	28	3	3	0	2	0	0	3	3
C08 Other and unspecified major salivary glands	17	15	13	9	1	2	0	0	0	0	3	4
C09 Tonsil	98	14	69	12	17	1	4	0	1	0	7	1
C10 Oropharynx	70	11	55	7	5	2	4	0	0	0	6	2
C11 Nasopharynx	40	12	30	10	7	0	3	2	0	0	0	0
C12 Pyriform sinus	162	21	122	12	20	6	8	2	0	0	12	1
C13 Hypopharynx	29	28	22	19	2	5	1	3	0	0	4	1
C14 Other and ill-defined sites in lip, oral cavity and pharynx	63	17	44	6	10	8	2	0	0	0	7	3
C15 Oesophagus	656	608	504	458	97	115	27	12	2	1	26	22
C16 Stomach	222	92	163	53	33	23	9	1	2	0	15	15
C17 Small intestine	21	13	17	7	0	1	1	3	0	0	3	2
C18 Colon	218	230	173	179	10	16	10	13	1	0	24	22
C19 Rectosigmoid junction	32	29	27	26	3	1	0	1	0	0	2	1
C20 Rectum	271	287	203	217	21	21	13	13	1	0	33	36
C21 Anus and anal canal	22	16	13	14	2	1	1	1	1	0	5	0
C22 Liver and intrahepatic bile ducts	119	45	96	31	6	2	11	4	0	0	6	8
C23 Gallbladder	8	30	5	20	3	5	0	2	0	0	0	3
C24 Other and unspecified parts of biliary tract	32	29	23	18	5	4	3	2	0	0	1	5
C25 Pancreas	60	40	48	31	7	2	3	4	0	0	2	3
C26 Other and ill-defined digestive organs	5	8	3	5	0	0	1	0	0	0	1	3
C30 Nasal cavity and middle ear	13	13	8	9	2	1	2	1	0	0	1	2
C31 Accessory sinuses	20	12	16	6	3	3	0	3	0	0	1	0
C32 Larynx	393	41	301	24	38	8	25	5	1	0	28	4
C33 Trachea	1	1	0	0	0	1	0	0	0	0	1	0
C34 Bronchus and lung	874	223	644	163	57	23	51	7	0	0	122	30
C37 Thymus	9	13	9	7	0	4	0	2	0	0	0	0
C38 Heart, mediastinum and pleura	22	8	18	7	0	1	1	0	0	0	3	0
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	18	12	1	0	0	0	0	0	0	0	17	12
C40 Bones, joints and articular cartilage of limbs	34	26	33	22	1	1	0	2	0	0	0	1

ICD O Code and Site	All		Sinhala		Tamil		Muslim		Other		Unknown	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
C41 Bones, joints and articular cartilage of other and unspecified sites	22	22	20	18	1	1	1	0	0	0	0	3
C42 Hematopoietic and reticuloendothelial systems	544	481	455	412	51	44	35	20	1	0	2	5
C44 Skin	198	119	128	69	23	13	9	7	1	0	37	30
C47 Peripheral nerves and autonomic nervous system	12	8	7	6	3	2	2	0	0	0	0	0
C48 Retroperitoneum and peritoneum	8	17	6	15	1	2	1	0	0	0	0	0
C49 Connective, subcutaneous and other soft tissues	73	76	61	61	7	5	4	8	1	0	0	2
C50 Breast	57	2293	40	1751	6	185	3	180	0	4	8	173
C51 Vulva		36		26		3		1		0		6
C52 Vagina		31		22		4		0		0		5
C53 Cervix uteri		879		625		130		30		3		91
C54 Corpus uteri		327		249		23		17		1		37
C55 Uterus, NOS		70		50		3		3		1		13
C56 Ovary		698		521		76		39		1		61
C57 Other and unspecified female genital organs		10		8		1		0		0		1
C58 Placenta		15		11		2		2		0		0
C60 Penis	88		64		12		2		2		8	
C61 Prostate gland	381		283		35		16		1		46	
C62 Testis	49		40		6		3		0		0	
C63 Other and unspecified male genital organs	10		6		2		0		0		2	
C64 Kidney	113	46	80	35	10	4	11	4	0	0	12	3
C65 Renal pelvis		2		2		0		0		0		0
C66 Ureter	2	1	1	0	0	0	0	0	0	0	1	1
C67 Bladder	260	51	145	39	20	3	19	0	1	0	75	9
C68 Other and unspecified urinary organs	1		0		0		1		0		0	
C69 Eye and adnexa	31	20	20	15	1	0	0	0	0	0	10	5
C70 Meninges	8	7	8	6	0	0	0	1	0	0	0	0
C71 Brain	149	106	129	84	11	12	9	8	0	0	0	2
C72 Spinal cord, cranial nerves and other parts of central nervous system	3	12	3	11	0	0	0	0	0	1	0	0
C73 Thyroid gland	180	816	146	694	11	40	9	45	0	3	14	34
C74 Adrenal gland	16	8	9	7	3	0	2	0	0	0	2	1
C75 Other endocrine glands and related structures	3	2	2	2	0	0	1	0	0	0	0	0
C76 Other and ill-defined sites	26	30	19	23	4	4	2	2	0	0	1	1
C77 Lymph nodes	345	211	271	173	35	16	24	15	1	0	14	7
C80 Unknown primary site	404	289	324	217	41	44	22	18	2	2	15	8
Total	7858	9030	5854	6751	772	980	399	511	21	18	812	770

Table 13: Cancer incidence by site and histological type, 2009

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C00 Lip						
8000 Neoplasm, malignant	2	4.5	3	15.8	5	7.9
8051 Verrucous carcinoma, NOS	2	4.5	1	5.3	3	4.8
8070 Squamous cell carcinoma, NOS	39	88.6	13	68.4	52	82.5
8071 Squamous cell carcinoma, keratinizing, NOS	1	2.3	1	5.3	2	3.2
8200 Adenoid cystic carcinoma	0	0.0	1	5.3	1	1.6
Total	44	100.0	19	100.0	63	100.0
C01 Base of tongue	No	%	No	%	No	%
8000 Neoplasm, malignant	13	11.8	0	0.0	13	10.6
8032 Spindle cell carcinoma, NOS	1	0.9	0	0.0	1	0.8
8052 Papillary squamous cell carcinoma	1	0.9	1	7.7	2	1.6
8070 Squamous cell carcinoma, NOS	89	80.9	9	69.2	98	79.7
8071 Squamous cell carcinoma, keratinizing, NOS	3	2.7	0	0.0	3	2.4
8083 Basaloid squamous cell carcinoma	3	2.7	1	7.7	4	3.3
8430 Mucoepidermoid carcinoma	0	0.0	1	7.7	1	0.8
8982 Malignant myoepithelioma	0	0.0	1	7.7	1	0.8
Total	110	100.0	13	100.0	123	100.0
C02 Other and unspecified parts of tongue	No	%	No	%	No	%
8000 Neoplasm, malignant	32	8.8	11	13.1	43	9.6
8051 Verrucous carcinoma, NOS	0	0.0	1	1.2	1	0.2
8052 Papillary squamous cell carcinoma	7	1.9	3	3.6	10	2.2
8070 Squamous cell carcinoma, NOS	308	84.6	66	78.6	374	83.5
8071 Squamous cell carcinoma, keratinizing, NOS	3	0.8	0	0.0	3	0.7
8074 Squamous cell carcinoma, spindle cell	1	0.3	0	0.0	1	0.2
8083 Basaloid squamous cell carcinoma	8	2.2	0	0.0	8	1.8
8140 Adenocarcinoma, NOS	0	0.0	3	3.6	3	0.7
8200 Adenoid cystic carcinoma	1	0.3	0	0.0	1	0.2
8480 Mucinous adenocarcinoma	1	0.3	0	0.0	1	0.2
8525 Polymorphous low grade adenocarcinoma	1	0.3	0	0.0	1	0.2
8720 Malignant melanoma, NOS	1	0.3	0	0.0	1	0.2
9120 Hemangiosarcoma	1	0.3	0	0.0	1	0.2
Total	364	100.0	84	100.0	448	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C03 Gum						
8000 Neoplasm, malignant	8	8.7	4	6.7	12	7.9
8010 Carcinoma, NOS	1	1.1	1	1.7	2	1.3
8021 Carcinoma, anaplastic, NOS	1	1.1	0	0.0	1	0.7
8051 Verrucous carcinoma, NOS	1	1.1	1	1.7	2	1.3
8070 Squamous cell carcinoma, NOS	75	81.5	48	80.0	123	80.9
8071 Squamous cell carcinoma, keratinizing, NOS	1	1.1	0	0.0	1	0.7
8200 Adenoid cystic carcinoma	0	0.0	1	1.7	1	0.7
8246 Neuroendocrine carcinoma, NOS	1	1.1	1	1.7	2	1.3
8310 Clear cell adenocarcinoma, NOS	0	0.0	1	1.7	1	0.7
8430 Mucoepidermoid carcinoma	1	1.1	2	3.3	3	2.0
8525 Polymorphous low grade adenocarcinoma	1	1.1	0	0.0	1	0.7
8720 Malignant melanoma, NOS	1	1.1	0	0.0	1	0.7
8900 Rhabdomyosarcoma, NOS	0	0.0	1	1.7	1	0.7
9591 Malignant lymphoma, non-Hodgkin, NOS	1	1.1	0	0.0	1	0.7
Total	92	100.0	60	100.0	152	100.0
C04 Floor of mouth	No	%	No	%	No	%
8000 Neoplasm, malignant	10	10.8	0	0.0	10	9.5
8010 Carcinoma, NOS	1	1.1	0	0.0	1	1.0
8051 Verrucous carcinoma, NOS	1	1.1	0	0.0	1	1.0
8070 Squamous cell carcinoma, NOS	78	83.9	11	91.7	89	84.8
8083 Basaloid squamous cell carcinoma	1	1.1	0	0.0	1	1.0
8200 Adenoid cystic carcinoma	0	0.0	1	8.3	1	1.0
8430 Mucoepidermoid carcinoma	2	2.2	0	0.0	2	1.9
Total	93	100.0	12	100.0	105	100.0
C05 Palate	No	%	No	%	No	%
8000 Neoplasm, malignant	12	9.0	2	6.5	14	8.5
8010 Carcinoma, NOS	1	0.7	0	0.0	1	0.6
8051 Verrucous carcinoma, NOS	1	0.7	0	0.0	1	0.6
8070 Squamous cell carcinoma, NOS	111	82.8	22	71.0	133	80.6
8075 Squamous cell carcinoma, adenoid	0	0.0	1	3.2	1	0.6
8083 Basaloid squamous cell carcinoma	2	1.5	0	0.0	2	1.2
8140 Adenocarcinoma, NOS	1	0.7	0	0.0	1	0.6
8200 Adenoid cystic carcinoma	2	1.5	3	9.7	5	3.0
8430 Mucoepidermoid carcinoma	3	2.2	3	9.7	6	3.6
8550 Acinar cell carcinoma	1	0.7	0	0.0	1	0.6
Total	134	100.0	31	100.0	165	100.0
C06 Other and unspecified parts of mouth	No	%	No	%	No	%
8000 Neoplasm, malignant	36	7.6	22	11.1	58	8.6
8010 Carcinoma, NOS	3	0.6	1	0.5	4	0.6
8051 Verrucous carcinoma, NOS	16	3.4	6	3.0	22	3.3
8070 Squamous cell carcinoma, NOS	406	85.7	157	79.3	563	83.8
8071 Squamous cell carcinoma, keratinizing, NOS	2	0.4	0	0.0	2	0.3
8072 Squamous cell carcinoma, large cell, nonkeratin	0	0.0	1	0.5	1	0.1
8075 Squamous cell carcinoma, adenoid	1	0.2	0	0.0	1	0.1
8076 Squamous cell carcinoma, microinvasive	3	0.6	0	0.0	3	0.4
8083 Basaloid squamous cell carcinoma	1	0.2	0	0.0	1	0.1
8140 Adenocarcinoma, NOS	1	0.2	2	1.0	3	0.4

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C03	Gum						
8200	Adenoid cystic carcinoma	3	0.6	0	0.0	3	0.4
8430	Mucoepidermoid carcinoma	1	0.2	4	2.0	5	0.7
8525	Polymorphous low grade adenocarcinoma	0	0.0	2	1.0	2	0.3
8550	Acinar cell carcinoma	0	0.0	1	0.5	1	0.1
8982	Malignant myoepithelioma	0	0.0	1	0.5	1	0.1
9364	Peripheral neuroectodermal tumor	1	0.2	0	0.0	1	0.1
9591	Malignant lymphoma, non-Hodgkin, NOS	0	0.0	1	0.5	1	0.1
	Total	474	100.0	198	100.0	672	100.0
C07	Parotid gland	No	%	No	%	No	%
8000	Neoplasm, malignant	4	11.4	2	5.6	6	8.5
8010	Carcinoma, NOS	0	0.0	1	2.8	1	1.4
8070	Squamous cell carcinoma, NOS	7	20.0	0	0.0	7	9.9
8140	Adenocarcinoma, NOS	1	2.9	4	11.1	5	7.0
8147	Basal cell adenocarcinoma	0	0.0	1	2.8	1	1.4
8200	Adenoid cystic carcinoma	2	5.7	1	2.8	3	4.2
8201	Cribriform carcinoma, NOS	0	0.0	1	2.8	1	1.4
8260	Papillary adenocarcinoma, NOS	1	2.9	0	0.0	1	1.4
8430	Mucoepidermoid carcinoma	13	37.1	17	47.2	30	42.3
8480	Mucinous adenocarcinoma	1	2.9	0	0.0	1	1.4
8500	Infiltrating duct carcinoma, NOS	1	2.9	0	0.0	1	1.4
8550	Acinar cell carcinoma	1	2.9	7	19.4	8	11.3
8941	Carcinoma in pleomorphic adenoma	3	8.6	1	2.8	4	5.6
8982	Malignant myoepithelioma	1	2.9	0	0.0	1	1.4
9591	Malignant lymphoma, non-Hodgkin, NOS	0	0.0	1	2.8	1	1.4
	Total	35	100.0	36	100.0	71	100.0
C08	Other and unspecified major salivary glands	No	%	No	%	No	%
8000	Neoplasm, malignant	0	0.0	2	13.3	2	6.3
8070	Squamous cell carcinoma, NOS	4	23.5	4	26.7	8	25.0
8140	Adenocarcinoma, NOS	1	5.9	0	0.0	1	3.1
8200	Adenoid cystic carcinoma	3	17.6	6	40.0	9	28.1
8310	Clear cell adenocarcinoma, NOS	1	5.9	0	0.0	1	3.1
8430	Mucoepidermoid carcinoma	3	17.6	1	6.7	4	12.5
8562	Epithelial-myoepithelial carcinoma	0	0.0	1	6.7	1	3.1
8941	Carcinoma in pleomorphic adenoma	2	11.8	1	6.7	3	9.4
9591	Malignant lymphoma, non-Hodgkin, NOS	2	11.8	0	0.0	2	6.3
9650	Hodgkin lymphoma, NOS	1	5.9	0	0.0	1	3.1
	Total	17	100.0	15	100.0	32	100.0
C09	Tonsil	No	%	No	%	No	%
8000	Neoplasm, malignant	8	8.2	1	7.1	9	8.0
8070	Squamous cell carcinoma, NOS	82	83.7	10	71.4	92	82.1
8071	Squamous cell carcinoma, keratinizing, NOS	2	2.0	1	7.1	3	2.7
8140	Adenocarcinoma, NOS	2	2.0	1	7.1	3	2.7
9591	Malignant lymphoma, non-Hodgkin, NOS	3	3.1	1	7.1	4	3.6
9680	Malignant lymphoma, large B-cell, diffuse, NOS	1	1.0	0	0.0	1	0.9
	Total	98	100.0	14	100.0	112	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C10 Oropharynx						
8000 Neoplasm, malignant	11	15.7	0	0.0	11	13.6
8070 Squamous cell carcinoma, NOS	55	78.6	10	90.9	65	80.2
8071 Squamous cell carcinoma, keratinizing, NOS	2	2.9	0	0.0	2	2.5
8072 Squamous cell carcinoma, large cell, nonkeratin	1	1.4	0	0.0	1	1.2
8200 Adenoid cystic carcinoma	0	0.0	1	9.1	1	1.2
8560 Adenosquamous carcinoma	1	1.4	0	0.0	1	1.2
Total	70	100.0	11	100.0	81	100.0
C11 Nasopharynx	No	%	No	%	No	%
8000 Neoplasm, malignant	14	35.0	5	41.7	19	36.5
8010 Carcinoma, NOS	4	10.0	3	25.0	7	13.5
8070 Squamous cell carcinoma, NOS	11	27.5	3	25.0	14	26.9
8072 Squamous cell carcinoma, large cell, nonkeratin	1	2.5	0	0.0	1	1.9
8082 Lymphoepithelial carcinoma	1	2.5	0	0.0	1	1.9
8140 Adenocarcinoma, NOS	3	7.5	0	0.0	3	5.8
8200 Adenoid cystic carcinoma	2	5.0	0	0.0	2	3.8
8246 Neuroendocrine carcinoma, NOS	1	2.5	0	0.0	1	1.9
8680 Paraganglioma, malignant	1	2.5	0	0.0	1	1.9
8980 Carcinosarcoma, NOS	0	0.0	1	8.3	1	1.9
9699 Marginal zone B-cell lymphoma, NOS	1	2.5	0	0.0	1	1.9
9734 Plasmacytoma, extramedullary	1	2.5	0	0.0	1	1.9
Total	40	100.0	12	100.0	52	100.0
C12 Pyriform sinus	No	%	No	%	No	%
8000 Neoplasm, malignant	10	6.2	2	9.5	12	6.6
8010 Carcinoma, NOS	1	0.6	1	4.8	2	1.1
8070 Squamous cell carcinoma, NOS	150	92.6	17	81.0	167	91.3
8074 Squamous cell carcinoma, spindle cell	0	0.0	1	4.8	1	0.5
8560 Adenosquamous carcinoma	1	0.6	0	0.0	1	0.5
Total	162	100.0	21	100.0	183	100.0
C13 Hypopharynx	No	%	No	%	No	%
8000 Neoplasm, malignant	1	3.4	1	3.6	2	3.5
8070 Squamous cell carcinoma, NOS	26	89.7	24	85.7	50	87.7
8071 Squamous cell carcinoma, keratinizing, NOS	1	3.4	3	10.7	4	7.0
8140 Adenocarcinoma, NOS	1	3.4	0	0.0	1	1.8
Total	29	100.0	28	100.0	57	100.0
C14 Other and ill-defined sites in lip, oral cavity and pharynx	No	%	No	%	No	%
8000 Neoplasm, malignant	4	6.3	1	5.9	5	6.3
8010 Carcinoma, NOS	2	3.2	0	0.0	2	2.5
8070 Squamous cell carcinoma, NOS	52	82.5	15	88.2	67	83.8
8071 Squamous cell carcinoma, keratinizing, NOS	1	1.6	1	5.9	2	2.5
8074 Squamous cell carcinoma, spindle cell	1	1.6	0	0.0	1	1.3
8083 Basaloid squamous cell carcinoma	1	1.6	0	0.0	1	1.3
8800 Sarcoma, NOS	1	1.6	0	0.0	1	1.3
9591 Malignant lymphoma, non-Hodgkin, NOS	1	1.6	0	0.0	1	1.3
Total	63	100.0	17	100.0	80	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C15 Oesophagus						
8000 Neoplasm, malignant	62	9.5	58	9.5	120	9.5
8010 Carcinoma, NOS	8	1.2	6	1.0	14	1.1
8041 Small cell carcinoma, NOS	1	0.2	1	0.2	2	0.2
8052 Papillary squamous cell carcinoma	1	0.2	0	0.0	1	0.1
8070 Squamous cell carcinoma, NOS	479	73.0	492	80.9	971	76.8
8071 Squamous cell carcinoma, keratinizing, NOS	7	1.1	9	1.5	16	1.3
8072 Squamous cell carcinoma, large cell, nonkeratinsing	0	0.0	2	0.3	2	0.2
8074 Squamous cell carcinoma, spindle cell	1	0.2	0	0.0	1	0.1
8083 Basaloid squamous cell carcinoma	1	0.2	1	0.2	2	0.2
8140 Adenocarcinoma, NOS	87	13.3	30	4.9	117	9.3
8246 Neuroendocrine carcinoma, NOS	0	0.0	3	0.5	3	0.2
8480 Mucinous adenocarcinoma	1	0.2	1	0.2	2	0.2
8490 Signet ring cell carcinoma	5	0.8	1	0.2	6	0.5
8560 Adenosquamous carcinoma	3	0.5	2	0.3	5	0.4
8802 Giant cell sarcoma	0	0.0	1	0.2	1	0.1
8936 Gastrointestinal stromal sarcoma	0	0.0	1	0.2	1	0.1
Total	656	100.0	608	100.0	1264	100.0
C16 Stomach	No	%	No	%	No	%
8000 Neoplasm, malignant	29	13.1	3	3.3	32	10.2
8010 Carcinoma, NOS	3	1.4	2	2.2	5	1.6
8051 Verrucous carcinoma, NOS	1	0.5	0	0.0	1	0.3
8070 Squamous cell carcinoma, NOS	14	6.3	17	18.5	31	9.9
8140 Adenocarcinoma, NOS	138	62.2	48	52.2	186	59.2
8142 Linitis plastica	0	0.0	1	1.1	1	0.3
8144 Adenocarcinoma, intestinal type	2	0.9	0	0.0	2	0.6
8145 Carcinoma, diffuse type	1	0.5	0	0.0	1	0.3
8211 Tubular adenocarcinoma	2	0.9	0	0.0	2	0.6
8240 Carcinoid tumor, NOS	0	0.0	2	2.2	2	0.6
8480 Mucinous adenocarcinoma	7	3.2	3	3.3	10	3.2
8481 Mucin-producing adenocarcinoma	2	0.9	1	1.1	3	1.0
8490 Signet ring cell carcinoma	16	7.2	7	7.6	23	7.3
8890 Leiomyosarcoma, NOS	1	0.5	0	0.0	1	0.3
8936 Gastrointestinal stromal sarcoma	6	2.7	8	8.7	14	4.5
Total	222	100.0	92	100.0	314	100.0
C17 Small intestine	No	%	No	%	No	%
8000 Neoplasm, malignant	4	19.0	1	7.7	5	14.7
8070 Squamous cell carcinoma, NOS	2	9.5	0	0.0	2	5.9
8140 Adenocarcinoma, NOS	7	33.3	6	46.2	13	38.2
8240 Carcinoid tumor, NOS	2	9.5	1	7.7	3	8.8
8480 Mucinous adenocarcinoma	1	4.8	0	0.0	1	2.9
8490 Signet ring cell carcinoma	0	0.0	1	7.7	1	2.9
8936 Gastrointestinal stromal sarcoma	3	14.3	2	15.4	5	14.7
9680 Malignant lymphoma, large B-cell, diffuse, NOS	0	0.0	1	7.7	1	2.9
9687 Burkitt lymphoma, NOS	1	4.8	0	0.0	1	2.9
9699 Marginal zone B-cell lymphoma, NOS	1	4.8	1	7.7	2	5.9
Total	21	100.0	13	100.0	34	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C18	Colon						
8000	Neoplasm, malignant	17	7.8	16	7.0	33	7.4
8010	Carcinoma, NOS	2	0.9	0	0.0	2	0.4
8070	Squamous cell carcinoma, NOS	2	0.9	2	0.9	4	0.9
8140	Adenocarcinoma, NOS	172	78.9	191	83.0	363	81.0
8240	Carcinoid tumor, NOS	1	0.5	2	0.9	3	0.7
8246	Neuroendocrine carcinoma, NOS	1	0.5	2	0.9	3	0.7
8260	Papillary adenocarcinoma, NOS	0	0.0	1	0.4	1	0.2
8262	Villous adenocarcinoma	1	0.5	0	0.0	1	0.2
8263	Adenocarcinoma in tubulovillous adenoma	1	0.5	0	0.0	1	0.2
8480	Mucinous adenocarcinoma	11	5.0	8	3.5	19	4.2
8481	Mucin-producing adenocarcinoma	2	0.9	2	0.9	4	0.9
8490	Signet ring cell carcinoma	2	0.9	3	1.3	5	1.1
8560	Adenosquamous carcinoma	1	0.5	1	0.4	2	0.4
8936	Gastrointestinal stromal sarcoma	0	0.0	1	0.4	1	0.2
9591	Malignant lymphoma, non-Hodgkin, NOS	3	1.4	1	0.4	4	0.9
9680	Malignant lymphoma, large B-cell, diffuse, NOS	1	0.5	0	0.0	1	0.2
9699	Marginal zone B-cell lymphoma, NOS	1	0.5	0	0.0	1	0.2
	Total	218	100.0	230	100.0	448	100.0
C19	Rectosigmoid junction						
8000	Neoplasm, malignant	4	12.5	2	6.9	6	9.8
8070	Squamous cell carcinoma, NOS	2	6.3	2	6.9	4	6.6
8140	Adenocarcinoma, NOS	25	78.1	24	82.8	49	80.3
8480	Mucinous adenocarcinoma	1	3.1	1	3.4	2	3.3
	Total	32	100.0	29	100.0	61	100.0
C20	Rectum						
8000	Neoplasm, malignant	36	13.3	17	5.9	53	9.5
8010	Carcinoma, NOS	0	0.0	2	0.7	2	0.4
8070	Squamous cell carcinoma, NOS	7	2.6	3	1.0	10	1.8
8071	Squamous cell carcinoma, keratinizing, NOS	0	0.0	1	0.3	1	0.2
8140	Adenocarcinoma, NOS	205	75.6	257	89.5	462	82.8
8211	Tubular adenocarcinoma	1	0.4	0	0.0	1	0.2
8246	Neuroendocrine carcinoma, NOS	0	0.0	1	0.3	1	0.2
8263	Adenocarcinoma in tubulovillous adenoma	0	0.0	1	0.3	1	0.2
8480	Mucinous adenocarcinoma	14	5.2	3	1.0	17	3.0
8481	Mucin-producing adenocarcinoma	1	0.4	0	0.0	1	0.2
8490	Signet ring cell carcinoma	4	1.5	1	0.3	5	0.9
8560	Adenosquamous carcinoma	1	0.4	0	0.0	1	0.2
8720	Malignant melanoma, NOS	2	0.7	1	0.3	3	0.5
	Total	271	100.0	287	100.0	558	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C21	Anus and anal canal						
8000	Neoplasm, malignant	2	9.1	1	6.3	3	7.9
8070	Squamous cell carcinoma, NOS	9	40.9	9	56.3	18	47.4
8071	Squamous cell carcinoma, keratinizing, NOS	0	0.0	1	6.3	1	2.6
8078	Squamous cell carcinoma with horn formation	1	4.5	0	0.0	1	2.6
8123	Basaloid carcinoma	0	0.0	1	6.3	1	2.6
8140	Adenocarcinoma, NOS	6	27.3	3	18.8	9	23.7
8262	Villous adenocarcinoma	1	4.5	0	0.0	1	2.6
8480	Mucinous adenocarcinoma	0	0.0	1	6.3	1	2.6
8560	Adenosquamous carcinoma	1	4.5	0	0.0	1	2.6
8720	Malignant melanoma, NOS	2	9.1	0	0.0	2	5.3
	Total	22	100.0	16	100.0	38	100.0
C22	Liver and intrahepatic bile ducts						
8000	Neoplasm, malignant	3	2.5	3	6.7	6	3.7
8140	Adenocarcinoma, NOS	1	0.8	1	2.2	2	1.2
8160	Cholangiocarcinoma	1	0.8	2	4.4	3	1.8
8162	Klatskin tumor	3	2.5	0	0.0	3	1.8
8170	Hepatocellular carcinoma, NOS	107	89.9	26	57.8	133	81.1
8171	Hepatocellular carcinoma, fibrolamellar	1	0.8	0	0.0	1	0.6
8310	Clear cell adenocarcinoma, NOS	0	0.0	1	2.2	1	0.6
8800	Sarcoma, NOS	0	0.0	1	2.2	1	0.6
8970	Hepatoblastoma	1	0.8	11	24.4	12	7.3
9591	Malignant lymphoma, non-Hodgkin, NOS	1	0.8	0	0.0	1	0.6
9754	Langerhans cell histiocytosis, disseminated	1	0.8	0	0.0	1	0.6
	Total	119	100.0	45	100.0	164	100.0
C23	Gallbladder						
8000	Neoplasm, malignant	2	25.0	6	20.0	8	21.1
8050	Papillary carcinoma, NOS	0	0.0	1	3.3	1	2.6
8070	Squamous cell carcinoma, NOS	1	12.5	0	0.0	1	2.6
8120	Transitional cell carcinoma, NOS	0	0.0	1	3.3	1	2.6
8140	Adenocarcinoma, NOS	4	50.0	22	73.3	26	68.4
8260	Papillary adenocarcinoma, NOS	1	12.5	0	0.0	1	2.6
	Total	8	100.0	30	100.0	38	100.0
C24	Other and unspecified parts of biliary tract						
8000	Neoplasm, malignant	2	6.3	2	6.9	4	6.6
8004	Malignant tumor, spindle cell type	1	3.1	0	0.0	1	1.6
8010	Carcinoma, NOS	0	0.0	1	3.4	1	1.6
8140	Adenocarcinoma, NOS	14	43.8	18	62.1	32	52.5
8160	Cholangiocarcinoma	15	46.9	7	24.1	22	36.1
8162	Klatskin tumor	0	0.0	1	3.4	1	1.6
	Total	32	100.0	29	100.0	61	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C25 Pancreas						
8000 Neoplasm, malignant	36	60.0	18	45.0	54	54.0
8013 Large cell neuroendocrine carcinoma	0	0.0	1	2.5	1	1.0
8140 Adenocarcinoma, NOS	19	31.7	16	40.0	35	35.0
8154 Mixed islet cell and exocrine adenocarcinoma	0	0.0	2	5.0	2	2.0
8246 Neuroendocrine carcinoma, NOS	0	0.0	1	2.5	1	1.0
8480 Mucinous adenocarcinoma	1	1.7	0	0.0	1	1.0
8481 Mucin-producing adenocarcinoma	1	1.7	0	0.0	1	1.0
8490 Signet ring cell carcinoma	1	1.7	0	0.0	1	1.0
8500 Infiltrating duct carcinoma, NOS	1	1.7	0	0.0	1	1.0
8550 Acinar cell carcinoma	1	1.7	1	2.5	2	2.0
8560 Adenosquamous carcinoma	0	0.0	1	2.5	1	1.0
Total	60	100.0	40	100.0	100	100.0
C26 Other and ill-defined digestive organs						
8000 Neoplasm, malignant	0	0.0	1	12.5	1	7.7
8140 Adenocarcinoma, NOS	3	60.0	2	25.0	5	38.5
8260 Papillary adenocarcinoma, NOS	0	0.0	1	12.5	1	7.7
8936 Gastrointestinal stromal sarcoma	2	40.0	1	12.5	3	23.1
9080 Teratoma, malignant, NOS	0	0.0	1	12.5	1	7.7
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0	1	12.5	1	7.7
9680 Malignant lymphoma, large B-cell, diffuse, NOS	0	0.0	1	12.5	1	7.7
Total	5	100.0	8	100.0	13	100.0
C30 Nasal cavity and middle ear						
8000 Neoplasm, malignant	1	7.7	0	0.0	1	3.8
8010 Carcinoma, NOS	1	7.7	0	0.0	1	3.8
8050 Papillary carcinoma, NOS	0	0.0	1	7.7	1	3.8
8070 Squamous cell carcinoma, NOS	4	30.8	5	38.5	9	34.6
8083 Basaloid squamous cell carcinoma	1	7.7	0	0.0	1	3.8
8120 Transitional cell carcinoma, NOS	0	0.0	1	7.7	1	3.8
8140 Adenocarcinoma, NOS	0	0.0	1	7.7	1	3.8
8200 Adenoid cystic carcinoma	0	0.0	2	15.4	2	7.7
8720 Malignant melanoma, NOS	1	7.7	0	0.0	1	3.8
9521 Olfactory neurocytoma	1	7.7	0	0.0	1	3.8
9522 Olfactory neuroblastoma	2	15.4	3	23.1	5	19.2
9591 Malignant lymphoma, non-Hodgkin, NOS	2	15.4	0	0.0	2	7.7
Total	13	100.0	13	100.0	26	100.0
C31 Accessory sinuses						
8000 Neoplasm, malignant	2	10.0	2	16.7	4	12.5
8010 Carcinoma, NOS	1	5.0	0	0.0	1	3.1
8052 Papillary squamous cell carcinoma	1	5.0	0	0.0	1	3.1
8070 Squamous cell carcinoma, NOS	10	50.0	7	58.3	17	53.1
8071 Squamous cell carcinoma, keratinizing, NOS	1	5.0	0	0.0	1	3.1
8120 Transitional cell carcinoma, NOS	1	5.0	0	0.0	1	3.1
8140 Adenocarcinoma, NOS	2	10.0	0	0.0	2	6.3
8430 Mucoepidermoid carcinoma	0	0.0	1	8.3	1	3.1
9591 Malignant lymphoma, non-Hodgkin, NOS	1	5.0	2	16.7	3	9.4
9714 Anaplastic large cell lymphoma, T cell and Null cell type	1	5.0	0	0.0	1	3.1
Total	20	100.0	12	100.0	32	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C32 Larynx						
8000 Neoplasm, malignant	28	7.1	3	7.3	31	7.1
8010 Carcinoma, NOS	1	0.3	2	4.9	3	0.7
8051 Verrucous carcinoma, NOS	1	0.3	0	0.0	1	0.2
8070 Squamous cell carcinoma, NOS	355	90.3	33	80.5	388	89.4
8071 Squamous cell carcinoma, keratinizing, NOS	4	1.0	1	2.4	5	1.2
8072 Squamous cell carcinoma, large cell, nonkeratin	3	0.8	0	0.0	3	0.7
8083 Basaloid squamous cell carcinoma	0	0.0	1	2.4	1	0.2
8200 Adenoid cystic carcinoma	0	0.0	1	2.4	1	0.2
8560 Adenosquamous carcinoma	1	0.3	0	0.0	1	0.2
Total	393	100.0	41	100.0	434	100.0
C33 Trachea						
8070 Squamous cell carcinoma, NOS	1	100.0	1	100.0	2	100.0
Total	1	100.0	1	100.0	2	100.0
C34 Bronchus and lung						
8000 Neoplasm, malignant	214	24.5	60	26.9	274	25.0
8004 Malignant tumor, spindle cell type	2	0.2	0	0.0	2	0.2
8010 Carcinoma, NOS	25	2.9	3	1.3	28	2.6
8012 Large cell carcinoma, NOS	9	1.0	2	0.9	11	1.0
8022 Pleomorphic carcinoma	1	0.1	1	0.4	2	0.2
8035 Carcinoma with osteoclast-like giant cells	0	0.0	1	0.4	1	0.1
8041 Small cell carcinoma, NOS	43	4.9	8	3.6	51	4.6
8042 Oat cell carcinoma	1	0.1	0	0.0	1	0.1
8045 Combined small cell carcinoma	1	0.1	0	0.0	1	0.1
8046 Non-small cell carcinoma	163	18.6	36	16.1	199	18.1
8070 Squamous cell carcinoma, NOS	222	25.4	27	12.1	249	22.7
8071 Squamous cell carcinoma, keratinizing, NOS	4	0.5	0	0.0	4	0.4
8072 Squamous cell carcinoma, large cell, nonkeratin	2	0.2	0	0.0	2	0.2
8074 Squamous cell carcinoma, spindle cell	1	0.1	0	0.0	1	0.1
8140 Adenocarcinoma, NOS	153	17.5	65	29.1	218	19.9
8200 Adenoid cystic carcinoma	0	0.0	2	0.9	2	0.2
8240 Carcinoid tumor, NOS	1	0.1	2	0.9	3	0.3
8246 Neuroendocrine carcinoma, NOS	2	0.2	0	0.0	2	0.2
8249 Atypical carcinoid tumor	2	0.2	0	0.0	2	0.2
8250 Bronchiolo-alveolar adenocarcinoma, NOS	11	1.3	10	4.5	21	1.9
8253 Bronchiolo-alveolar carcinoma, mucinous	0	0.0	1	0.4	1	0.1
8260 Papillary adenocarcinoma, NOS	10	1.1	0	0.0	10	0.9
8430 Mucoepidermoid carcinoma	2	0.2	0	0.0	2	0.2
8480 Mucinous adenocarcinoma	1	0.1	0	0.0	1	0.1
8481 Mucin-producing adenocarcinoma	2	0.2	0	0.0	2	0.2
8490 Signet ring cell carcinoma	0	0.0	1	0.4	1	0.1
8560 Adenosquamous carcinoma	1	0.1	0	0.0	1	0.1
8800 Sarcoma, NOS	0	0.0	1	0.4	1	0.1
8801 Spindle cell sarcoma	1	0.1	0	0.0	1	0.1
8806 Desmoplastic small round cell tumor	0	0.0	1	0.4	1	0.1
8890 Leiomyosarcoma, NOS	0	0.0	1	0.4	1	0.1
9650 Hodgkin lymphoma, NOS	0	0.0	1	0.4	1	0.1
Total	874	100.0	223	100.0	1097	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C37 Thymus						
8000 Neoplasm, malignant	1	11.1	0	0.0	1	4.5
8430 Mucoepidermoid carcinoma	0	0.0	1	7.7	1	4.5
8580 Thymoma, malignant, NOS	7	77.8	8	61.5	15	68.2
8582 Thymoma, type A, malignant	0	0.0	1	7.7	1	4.5
8585 Thymoma, type B2, malignant	0	0.0	1	7.7	1	4.5
8586 Thymic carcinoma, NOS	0	0.0	2	15.4	2	9.1
9679 Mediastinal large B-cell lymphoma	1	11.1	0	0.0	1	4.5
Total	9	100.0	13	100.0	22	100.0
C38 Heart, mediastinum and pleura	No	%	No	%	No	%
8000 Neoplasm, malignant	5	22.7	2	25.0	7	23.3
8801 Spindle cell sarcoma	0	0.0	1	12.5	1	3.3
9050 Mesothelioma, malignant	3	13.6	3	37.5	6	20.0
9064 Germinoma	2	9.1	0	0.0	2	6.7
9080 Teratoma, malignant, NOS	4	18.2	0	0.0	4	13.3
9085 Mixed germ cell tumor	1	4.5	0	0.0	1	3.3
9500 Neuroblastoma, NOS	0	0.0	1	12.5	1	3.3
9590 Malignant lymphoma, NOS	1	4.5	0	0.0	1	3.3
9591 Malignant lymphoma, non-Hodgkin, NOS	3	13.6	0	0.0	3	10.0
9650 Hodgkin lymphoma, NOS	1	4.5	1	12.5	2	6.7
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	4.5	0	0.0	1	3.3
9727 Precursor cell lymphoblastic lymphoma, NOS	1	4.5	0	0.0	1	3.3
Total	22	100.0	8	100.0	30	100.0
C39 Other and ill-defined sites within respiratory system and intrathoracic organs	No	%	No	%	No	%
8000 Neoplasm, malignant	2	11.1	1	8.3	3	10.0
8010 Carcinoma, NOS	5	27.8	5	41.7	10	33.3
8070 Squamous cell carcinoma, NOS	7	38.9	1	8.3	8	26.7
8071 Squamous cell carcinoma, keratinizing, NOS	1	5.6	0	0.0	1	3.3
8140 Adenocarcinoma, NOS	3	16.7	4	33.3	7	23.3
9650 Hodgkin lymphoma, NOS	0	0.0	1	8.3	1	3.3
Total	18	100.0	12	100.0	30	100.0
C40 Bones, joints and articular cartilage of limbs	No	%	No	%	No	%
9180 Osteosarcoma, NOS	23	67.6	12	46.2	35	58.3
9181 Chondroblastic osteosarcoma	1	2.9	2	7.7	3	5.0
9185 Small cell osteosarcoma	1	2.9	0	0.0	1	1.7
9220 Chondrosarcoma, NOS	1	2.9	2	7.7	3	5.0
9231 Myxoid chondrosarcoma	0	0.0	1	3.8	1	1.7
9250 Giant cell tumor of bone, malignant	3	8.8	5	19.2	8	13.3
9260 Ewing sarcoma	4	11.8	3	11.5	7	11.7
9680 Malignant lymphoma, large B-cell, diffuse, NOS	1	2.9	0	0.0	1	1.7
9731 Plasmacytoma, NOS	0	0.0	1	3.8	1	1.7
Total	34	100.0	26	100.0	60	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C41 Bones, joints and articular cartilage of other and unspecified sites						
8000 Neoplasm, malignant	0	0.0	1	4.5	1	2.3
9180 Osteosarcoma, NOS	5	22.7	5	22.7	10	22.7
9220 Chondrosarcoma, NOS	2	9.1	3	13.6	5	11.4
9250 Giant cell tumor of bone, malignant	0	0.0	3	13.6	3	6.8
9260 Ewing sarcoma	8	36.4	7	31.8	15	34.1
9310 Ameloblastoma, malignant	0	0.0	1	4.5	1	2.3
9731 Plasmacytoma, NOS	6	27.3	2	9.1	8	18.2
Total	21	100.0	22	100.0	43	100.0

C42 Hematopoietic and reticuloendothelial systems	No	%	No	%	No	%
9590 Malignant lymphoma, NOS	1	0.2	1	0.2	2	0.2
9591 Malignant lymphoma, non-Hodgkin, NOS	6	1.1	4	0.8	10	1.0
9650 Hodgkin lymphoma, NOS	1	0.2	1	0.2	2	0.2
9663 Hodgkin lymphoma, nodular sclerosis, NOS	1	0.2	0	0.0	1	0.1
9670 Malignant lymphoma, small B lymphocytic, NOS	1	0.2	0	0.0	1	0.1
9671 Malignant lymphoma, lymphoplasmacytic	1	0.2	1	0.2	2	0.2
9689 Splenic marginal zone B-cell lymphoma	0	0.0	1	0.2	1	0.1
9702 Mature T-cell lymphoma, NOS	1	0.2	0	0.0	1	0.1
9727 Precursor cell lymphoblastic lymphoma, NOS	1	0.2	0	0.0	1	0.1
9731 Plasmacytoma, NOS	3	0.6	3	0.6	6	0.6
9732 Multiple myeloma	107	19.7	122	25.4	229	22.3
9733 Plasma cell leukemia	1	0.2	1	0.2	2	0.2
9761 Waldenstrom macroglobulinemia	1	0.2	0	0.0	1	0.1
9801 Acute leukemia, NOS	1	0.2	1	0.2	2	0.2
9823 B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma	19	3.5	17	3.5	36	3.5
9826 Burkitt cell leukemia	2	0.4	1	0.2	3	0.3
9831 T-cell large granular lymphocytic leukemia	1	0.2	0	0.0	1	0.1
9832 Prolymphocytic leukemia, NOS	2	0.4	5	1.0	7	0.7
9835 Precursor cell lymphoblastic leukemia, NOS	158	29.0	104	21.6	262	25.6
9836 Precursor B-cell lymphoblastic leukemia	3	0.6	1	0.2	4	0.4
9840 Acute myeloid leukemia, M6 type	1	0.2	0	0.0	1	0.1
9860 Myeloid leukemia, NOS	5	0.9	2	0.4	7	0.7
9861 Acute myeloid leukemia, NOS	24	4.4	29	6.0	53	5.2
9863 Chronic myeloid leukemia, NOS	75	13.8	64	13.3	139	13.6
9866 Acute promyelocytic leukemia, t(15;17)(q22;q11-12)	7	1.3	17	3.5	24	2.3
9867 Acute myelomonocytic leukemia	23	4.2	18	3.7	41	4.0
9872 Acute myeloid leukemia	2	0.4	2	0.4	4	0.4
9875 Chronic myelogenous leukemia, BCR/ABL positive	1	0.2	0	0.0	1	0.1
9891 Acute monocytic leukemia	8	1.5	6	1.2	14	1.4
9910 Acute megakaryoblastic leukemia	3	0.6	3	0.6	6	0.6
9920 Therapy -related acute myeloid leukemia, NOS	1	0.2	0	0.0	1	0.1

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C42 Hematopoietic and reticuloendothelial systems						
9931 Acute panmyelosis with myelofibrosis	3	0.6	6	1.2	9	0.9
9940 Hairy cell leukemia	3	0.6	0	0.0	3	0.3
9945 Chronic myelomonocytic leukemia, NOS	2	0.4	1	0.2	3	0.3
9946 Juvenile myelomonocytic leukemia	1	0.2	1	0.2	2	0.2
9950 Polycythemia vera	8	1.5	7	1.5	15	1.5
9961 Myelofibrosis with myeloid metaplasia	1	0.2	1	0.2	2	0.2
9962 Essential thrombocythemia	2	0.4	0	0.0	2	0.2
9980 Refractory anemia	0	0.0	1	0.2	1	0.1
9982 Refractory anemia with sideroblasts	1	0.2	0	0.0	1	0.1
9989 Myelodysplastic syndrome, NOS	27	5.0	23	4.8	50	4.9
Total	544	100.0	481	100.0	1025	100.0
C44 Skin	No	%	No	%	No	%
8000 Neoplasm, malignant	1	0.5	1	0.8	2	0.6
8004 Malignant tumor, spindle cell type	1	0.5	0	0.0	1	0.3
8010 Carcinoma, NOS	1	0.5	0	0.0	1	0.3
8032 Spindle cell carcinoma, NOS	5	2.5	1	0.8	6	1.9
8051 Verrucous carcinoma, NOS	2	1.0	1	0.8	3	0.9
8070 Squamous cell carcinoma, NOS	105	53.0	43	36.1	148	46.7
8071 Squamous cell carcinoma, keratinizing, NOS	4	2.0	2	1.7	6	1.9
8083 Basaloid squamous cell carcinoma	1	0.5	2	1.7	3	0.9
8090 Basal cell carcinoma, NOS	28	14.1	28	23.5	56	17.7
8094 Basosquamous carcinoma	3	1.5	3	2.5	6	1.9
8097 Basal cell carcinoma, nodular	1	0.5	0	0.0	1	0.3
8140 Adenocarcinoma, NOS	1	0.5	0	0.0	1	0.3
8147 Basal cell adenocarcinoma	1	0.5	0	0.0	1	0.3
8200 Adenoid cystic carcinoma	1	0.5	0	0.0	1	0.3
8390 Skin appendage carcinoma	2	1.0	0	0.0	2	0.6
8402 Nodular hidradenoma, malignant	0	0.0	1	0.8	1	0.3
8410 Sebaceous adenocarcinoma	1	0.5	4	3.4	5	1.6
8413 Eccrine adenocarcinoma	2	1.0	0	0.0	2	0.6
8430 Mucoepidermoid carcinoma	0	0.0	1	0.8	1	0.3
8480 Mucinous adenocarcinoma	0	0.0	1	0.8	1	0.3
8720 Malignant melanoma, NOS	24	12.1	18	15.1	42	13.2
8721 Nodular melanoma	1	0.5	1	0.8	2	0.6
8744 Acral lentiginous melanoma, malignant	3	1.5	0	0.0	3	0.9
8804 Epithelioid sarcoma	1	0.5	0	0.0	1	0.3
8832 Dermatofibrosarcoma, NOS	3	1.5	3	2.5	6	1.9
9590 Malignant lymphoma, NOS	0	0.0	1	0.8	1	0.3
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0	3	2.5	3	0.9
9700 Mycosis fungoides	5	2.5	3	2.5	8	2.5
9702 Mature T-cell lymphoma, NOS	1	0.5	0	0.0	1	0.3
9709 Cutaneous T-cell lymphoma, NOS	0	0.0	1	0.8	1	0.3
9754 Langerhans cell histiocytosis, disseminated	0	0.0	1	0.8	1	0.3
Total	198	100.0	119	100.0	317	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C47 Peripheral nerves and autonomic nervous system						
9364 Peripheral neuroectodermal tumor	1	8.3	1	12.5	2	10.0
9473 Primitive neuroectodermal tumor, NOS	1	8.3	1	12.5	2	10.0
9490 Ganglioneuroblastoma	1	8.3	0	0.0	1	5.0
9500 Neuroblastoma, NOS	1	8.3	2	25.0	3	15.0
9540 Malignant peripheral nerve sheath tumour	8	66.7	4	50.0	12	60.0
Total	12	100.0	8	100.0	20	100.0
C48 Retroperitoneum and peritoneum	No	%	No	%	No	%
8000 Neoplasm, malignant	0	0.0	5	29.4	5	20.0
8002 Malignant tumour, small cell type	1	12.5	0	0.0	1	4.0
8004 Malignant tumor, spindle cell type	0	0.0	1	5.9	1	4.0
8800 Sarcoma, NOS	0	0.0	1	5.9	1	4.0
8801 Spindle cell sarcoma	0	0.0	1	5.9	1	4.0
8802 Giant cell sarcoma	1	12.5	0	0.0	1	4.0
8806 Desmoplastic small round cell tumor	0	0.0	1	5.9	1	4.0
8815 Solitary fibrous tumour, malignant	0	0.0	1	5.9	1	4.0
8850 Liposarcoma, NOS	0	0.0	2	11.8	2	8.0
8852 Myxoid liposarcoma	1	12.5	0	0.0	1	4.0
8854 Pleomorphic liposarcoma	1	12.5	0	0.0	1	4.0
8890 Leiomyosarcoma, NOS	1	12.5	1	5.9	2	8.0
8900 Rhabdomyosarcoma, NOS	0	0.0	1	5.9	1	4.0
9050 Mesothelioma, malignant	1	12.5	0	0.0	1	4.0
9064 Germinoma	0	0.0	1	5.9	1	4.0
9071 Yolk sac tumour	1	12.5	1	5.9	2	8.0
9540 Malignant peripheral nerve sheath tumour	0	0.0	1	5.9	1	4.0
9591 Malignant lymphoma, non-Hodgkin, NOS	1	12.5	0	0.0	1	4.0
Total	8	100.0	17	100.0	25	100.0
C49 Connective, subcutaneous and other soft tissues	No	%	No	%	No	%
8000 Neoplasm, malignant	3	4.1	0	0.0	3	2.0
8004 Malignant tumor, spindle cell type	5	6.8	2	2.6	7	4.7
8032 Spindle cell carcinoma, NOS	0	0.0	2	2.6	2	1.3
8800 Sarcoma, NOS	16	21.9	16	21.1	32	21.5
8801 Spindle cell sarcoma	4	5.5	7	9.2	11	7.4
8802 Giant cell sarcoma	2	2.7	7	9.2	9	6.0
8803 Small cell sarcoma	0	0.0	1	1.3	1	0.7
8806 Desmoplastic small round cell tumor	2	2.7	1	1.3	3	2.0
8810 Fibrosarcoma, NOS	1	1.4	2	2.6	3	2.0
8811 Fibromyxosarcoma	3	4.1	8	10.5	11	7.4
8814 Infantile fibrosarcoma	1	1.4	0	0.0	1	0.7
8830 Malignant fibrous histiocytoma	2	2.7	1	1.3	3	2.0
8850 Liposarcoma, NOS	7	9.6	3	3.9	10	6.7
8852 Myxoid liposarcoma	2	2.7	1	1.3	3	2.0
8855 Mixed liposarcoma	0	0.0	1	1.3	1	0.7
8890 Leiomyosarcoma, NOS	8	11.0	4	5.3	12	8.1
8895 Myosarcoma	0	0.0	1	1.3	1	0.7
8900 Rhabdomyosarcoma, NOS	3	4.1	3	3.9	6	4.0
8910 Embryonal rhabdomyosarcoma, NOS	3	4.1	1	1.3	4	2.7

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C49 Connective, subcutaneous and other soft tissues						
8920 Alveolar rhabdomyosarcoma	0	0.0	1	1.3	1	0.7
9040 Synovial sarcoma, NOS	5	6.8	6	7.9	11	7.4
9120 Hemangiosarcoma	0	0.0	1	1.3	1	0.7
9133 Epithelioid hemangioendothelioma, malignant	0	0.0	1	1.3	1	0.7
9150 Hemangiopericytoma, malignant	1	1.4	1	1.3	2	1.3
9240 Mesenchymal chondrosarcoma	1	1.4	0	0.0	1	0.7
9252 Malignant tenosynovial giant cell tumour	0	0.0	1	1.3	1	0.7
9370 Chordoma, NOS	1	1.4	1	1.3	2	1.3
9540 Malignant peripheral nerve sheath tumour	0	0.0	1	1.3	1	0.7
9581 Alveolar soft part sarcoma	3	4.1	2	2.6	5	3.4
Total	73	100.0	76	100.0	149	100.0
C50 Breast						
8000 Neoplasm, malignant	5	8.8	292	12.7	297	12.6
8010 Carcinoma, NOS	1	1.8	17	0.7	18	0.8
8021 Carcinoma, anaplastic, NOS	0	0.0	1	0.0	1	0.0
8032 Spindle cell carcinoma, NOS	0	0.0	2	0.1	2	0.1
8050 Papillary carcinoma, NOS	0	0.0	14	0.6	14	0.6
8070 Squamous cell carcinoma, NOS	0	0.0	2	0.1	2	0.1
8140 Adenocarcinoma, NOS	4	7.0	13	0.6	17	0.7
8201 Cribriform carcinoma, NOS	0	0.0	3	0.1	3	0.1
8211 Tubular adenocarcinoma	0	0.0	2	0.1	2	0.1
8246 Neuroendocrine carcinoma, NOS	0	0.0	2	0.1	2	0.1
8260 Papillary adenocarcinoma, NOS	1	1.8	3	0.1	4	0.2
8401 Apocrine adenocarcinoma	0	0.0	2	0.1	2	0.1
8480 Mucinous adenocarcinoma	0	0.0	19	0.8	19	0.8
8500 Infiltrating duct carcinoma, NOS	40	70.2	1797	78.4	1837	78.2
8501 Comedocarcinoma, NOS	0	0.0	2	0.1	2	0.1
8503 Intraductal papillary adenocarcinoma with invasion	1	1.8	1	0.0	2	0.1
8504 Intracystic carcinoma, NOS	0	0.0	3	0.1	3	0.1
8510 Medullary carcinoma, NOS	1	1.8	9	0.4	10	0.4
8520 Lobular carcinoma, NOS	1	1.8	80	3.5	81	3.4
8522 Infiltrating duct and lobular carcinoma	1	1.8	9	0.4	10	0.4
8523 Infiltrating duct mixed with other types of carcinoma	0	0.0	1	0.0	1	0.0
8524 Infiltrating lobular mixed with other types of carcinoma	0	0.0	1	0.0	1	0.0
8530 Inflammatory carcinoma	0	0.0	1	0.0	1	0.0
8540 Paget disease, mammary	0	0.0	3	0.1	3	0.1
8541 Paget disease and infiltrating duct carcinoma of breast	0	0.0	1	0.0	1	0.0
8543 Paget disease and intraductal carcinoma of breast	0	0.0	1	0.0	1	0.0
8560 Adenosquamous carcinoma	1	1.8	2	0.1	3	0.1
8800 Sarcoma, NOS	0	0.0	1	0.0	1	0.0
8801 Spindle cell sarcoma	0	0.0	1	0.0	1	0.0
8810 Fibrosarcoma, NOS	0	0.0	1	0.0	1	0.0
8811 Fibromyxosarcoma	0	0.0	1	0.0	1	0.0
9020 Phyllodes tumor, malignant	1	1.8	4	0.2	5	0.2
9120 Hemangiosarcoma	0	0.0	1	0.0	1	0.0
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0	1	0.0	1	0.0
Total	57	100.0	2293	100.0	2350	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C51 Vulva						
8000 Neoplasm, malignant			2	5.6	2	5.6
8070 Squamous cell carcinoma, NOS			23	63.9	23	63.9
8071 Squamous cell carcinoma, keratinizing, NOS			5	13.9	5	13.9
8072 Squamous cell carcinoma, large cell, nonkeratin			1	2.8	1	2.8
8147 Basal cell adenocarcinoma			1	2.8	1	2.8
8260 Papillary adenocarcinoma, NOS			1	2.8	1	2.8
8720 Malignant melanoma, NOS			1	2.8	1	2.8
8800 Sarcoma, NOS			1	2.8	1	2.8
8802 Giant cell sarcoma			1	2.8	1	2.8
Total			36	100.0	36	100.0
C52 Vagina	No	%	No	%	No	%
8000 Neoplasm, malignant			3	9.7	3	9.7
8004 Malignant tumor, spindle cell type			1	3.2	1	3.2
8070 Squamous cell carcinoma, NOS			18	58.1	18	58.1
8071 Squamous cell carcinoma, keratinizing, NOS			1	3.2	1	3.2
8072 Squamous cell carcinoma, large cell, keratinizing, NOS			3	9.7	3	9.7
8140 Adenocarcinoma, NOS			1	3.2	1	3.2
8260 Papillary adenocarcinoma, NOS			1	3.2	1	3.2
8720 Malignant melanoma, NOS			1	3.2	1	3.2
8800 Sarcoma, NOS			1	3.2	1	3.2
8890 Leiomyosarcoma, NOS			1	3.2	1	3.2
Total			31	100.0	31	100.0
C53 Cervix uteri	No	%	No	%	No	%
8000 Neoplasm, malignant			103	11.7	103	11.7
8002 Malignant tumour, small cell type			1	0.1	1	0.1
8010 Carcinoma, NOS			3	0.3	3	0.3
8012 Large cell carcinoma, NOS			1	0.1	1	0.1
8041 Small cell carcinoma, NOS			1	0.1	1	0.1
8052 Papillary squamous cell carcinoma			2	0.2	2	0.2
8070 Squamous cell carcinoma, NOS			431	49.0	431	49.0
8071 Squamous cell carcinoma, keratinizing, NOS			89	10.1	89	10.1
8072 Squamous cell carcinoma, large cell, keratinizing, NOS			190	21.6	190	21.6
8073 Squamous cell carcinoma, small cell, keratinizing, NOS			3	0.3	3	0.3
8074 Squamous cell carcinoma, spindle cell			1	0.1	1	0.1
8076 Squamous cell carcinoma, microinvasive			3	0.3	3	0.3
8083 Basaloid squamous cell carcinoma			1	0.1	1	0.1
8098 Adenoid basal carcinoma			1	0.1	1	0.1
8140 Adenocarcinoma, NOS			37	4.2	37	4.2
8200 Adenoid cystic carcinoma			1	0.1	1	0.1
8260 Papillary adenocarcinoma, NOS			3	0.3	3	0.3
8310 Clear cell adenocarcinoma, NOS			1	0.1	1	0.1
8481 Mucin-producing adenocarcinoma			1	0.1	1	0.1
8560 Adenosquamous carcinoma			5	0.6	5	0.6
8800 Sarcoma, NOS			1	0.1	1	0.1
Total			879	100.0	879	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C54 Corpus uteri						
8000 Neoplasm, malignant			16	4.9	16	4.9
8070 Squamous cell carcinoma, NOS			3	0.9	3	0.9
8071 Squamous cell carcinoma, keratinizing, NOS			1	0.3	1	0.3
8072 Squamous cell carcinoma, large cell, keratinizing, NOS			3	0.9	3	0.9
8140 Adenocarcinoma, NOS			89	27.2	89	27.2
8260 Papillary adenocarcinoma, NOS			12	3.7	12	3.7
8310 Clear cell adenocarcinoma, NOS			5	1.5	5	1.5
8380 Endometrioid adenocarcinoma, NOS			169	51.7	169	51.7
8441 Serous cystadenocarcinoma, NOS			3	0.9	3	0.9
8460 Papillary serous cystadenocarcinoma			2	0.6	2	0.6
8480 Mucinous adenocarcinoma			1	0.3	1	0.3
8560 Adenosquamous carcinoma			4	1.2	4	1.2
8930 Endometrial stromal sarcoma, NOS			11	3.4	11	3.4
8931 Endometrial stromal sarcoma, low grade			1	0.3	1	0.3
8950 Mullerian mixed tumor			4	1.2	4	1.2
8980 Carcinosarcoma, NOS			3	0.9	3	0.9
Total			327	100.0	327	100.0
C55 Uterus, NOS	No	%	No	%	No	%
8000 Neoplasm, malignant			6	8.6	6	8.6
8010 Carcinoma, NOS			1	1.4	1	1.4
8070 Squamous cell carcinoma, NOS			2	2.9	2	2.9
8140 Adenocarcinoma, NOS			21	30.0	21	30.0
8260 Papillary adenocarcinoma, NOS			1	1.4	1	1.4
8310 Clear cell adenocarcinoma, NOS			1	1.4	1	1.4
8460 Papillary serous cystadenocarcinoma			2	2.9	2	2.9
8560 Adenosquamous carcinoma			2	2.9	2	2.9
8800 Sarcoma, NOS			4	5.7	4	5.7
8801 Spindle cell sarcoma			1	1.4	1	1.4
8890 Leiomyosarcoma, NOS			16	22.9	16	22.9
8896 Myxoid leiomyosarcoma			1	1.4	1	1.4
8935 Stromal sarcoma, NOS			1	1.4	1	1.4
8950 Mullerian mixed tumor			1	1.4	1	1.4
8951 Mesodermal mixed tumour			1	1.4	1	1.4
8980 Carcinosarcoma, NOS			6	8.6	6	8.6
9100 Choriocarcinoma, NOS			3	4.3	3	4.3
Total			70	100.0	70	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C56	Ovary						
8000	Neoplasm, malignant			120	17.2	120	17.2
8002	Malignant tumour, small cell type			1	0.1	1	0.1
8010	Carcinoma, NOS			5	0.7	5	0.7
8070	Squamous cell carcinoma, NOS			1	0.1	1	0.1
8072	Squamous cell carcinoma, large cell, keratinizing, NOS			1	0.1	1	0.1
8120	Transitional cell carcinoma, NOS			1	0.1	1	0.1
8140	Adenocarcinoma, NOS			91	13.0	91	13.0
8246	Neuroendocrine carcinoma, NOS			1	0.1	1	0.1
8260	Papillary adenocarcinoma, NOS			42	6.0	42	6.0
8310	Clear cell adenocarcinoma, NOS			20	2.9	20	2.9
8380	Endometrioid adenocarcinoma, NOS			41	5.9	41	5.9
8440	Cystadenocarcinoma, NOS			7	1.0	7	1.0
8441	Serous cystadenocarcinoma, NOS			94	13.5	94	13.5
8450	Papillary cystadenocarcinoma, NOS			5	0.7	5	0.7
8460	Papillary serous cystadenocarcinoma			130	18.6	130	18.6
8461	Serous surface papillary carcinoma			2	0.3	2	0.3
8470	Mucinous cystadenocarcinoma, NOS			32	4.6	32	4.6
8471	Papillary mucinous cystadenocarcinoma			10	1.4	10	1.4
8480	Mucinous adenocarcinoma			22	3.2	22	3.2
8490	Signet ring cell carcinoma			1	0.1	1	0.1
8620	Granulosa cell tumor, malignant			25	3.6	25	3.6
8631	Sertoli-Leydig cell tumour, poorly differentiated			1	0.1	1	0.1
8670	Steroid cell tumour, malignant			2	0.3	2	0.3
8810	Fibrosarcoma, NOS			1	0.1	1	0.1
8950	Mullerian mixed tumor			2	0.3	2	0.3
8980	Carcinosarcoma, NOS			1	0.1	1	0.1
9015	Mucinous adenocarcinofibroma			1	0.1	1	0.1
9060	Dysgerminoma			23	3.3	23	3.3
9064	Germinoma			1	0.1	1	0.1
9070	Embryonal carcinoma, NOS			1	0.1	1	0.1
9071	Yolk sac tumour			2	0.3	2	0.3
9080	Teratoma, malignant, NOS			6	0.9	6	0.9
9085	Mixed germ cell tumor			5	0.7	5	0.7
	Total			698	100.0	698	100.0
C57	Other and unspecified female genital organs	No	%	No	%	No	%
8000	Neoplasm, malignant			2	20.0	2	20.0
8070	Squamous cell carcinoma, NOS			1	10.0	1	10.0
8140	Adenocarcinoma, NOS			4	40.0	4	40.0
8260	Papillary adenocarcinoma, NOS			1	10.0	1	10.0
8310	Clear cell adenocarcinoma, NOS			1	10.0	1	10.0
8800	Sarcoma, NOS			1	10.0	1	10.0
	Total			10	100.0	10	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C58 Placenta						
8000 Neoplasm, malignant			1	6.7	1	6.7
9100 Choriocarcinoma, NOS			12	80.0	12	80.0
9105 Trophoblastic tumor, epithelioid			2	13.3	2	13.3
Total			15	100.0	15	100.0
C60 Penis	No	%	No	%	No	%
8000 Neoplasm, malignant	7	8.0			7	8.0
8010 Carcinoma, NOS	1	1.1			1	1.1
8051 Verrucous carcinoma, NOS	1	1.1			1	1.1
8070 Squamous cell carcinoma, NOS	76	86.4			76	86.4
8071 Squamous cell carcinoma, keratinizing, NOS	2	2.3			2	2.3
8140 Adenocarcinoma, NOS	1	1.1			1	1.1
Total	88	100.0			88	100.0
C61 Prostate gland	No	%	No	%	No	%
8000 Neoplasm, malignant	106	27.8			106	27.8
8010 Carcinoma, NOS	1	0.3			1	0.3
8070 Squamous cell carcinoma, NOS	3	0.8			3	0.8
8120 Transitional cell carcinoma, NOS	1	0.3			1	0.3
8140 Adenocarcinoma, NOS	186	48.8			186	48.8
8263 Adenocarcinoma in tubulovillous adenoma	1	0.3			1	0.3
8310 Clear cell adenocarcinoma, NOS	1	0.3			1	0.3
8480 Mucinous adenocarcinoma	1	0.3			1	0.3
8500 Infiltrating duct carcinoma, NOS	2	0.5			2	0.5
8550 Acinar cell carcinoma	77	20.2			77	20.2
8801 Spindle cell sarcoma	1	0.3			1	0.3
9690 Follicular lymphoma, NOS	1	0.3			1	0.3
Total	381	100.0			381	100.0
C62 Testis	No	%	No	%	No	%
8000 Neoplasm, malignant	2	4.1			2	4.1
8650 Leydig cell tumor, malignant	1	2.0			1	2.0
9061 Seminoma, NOS	15	30.6			15	30.6
9062 Seminoma, anaplastic	2	4.1			2	4.1
9064 Germinoma	4	8.2			4	8.2
9065 Germ cell tumor, nonseminomatous	4	8.2			4	8.2
9070 Embryonal carcinoma, NOS	1	2.0			1	2.0
9071 Yolk sac tumour	3	6.1			3	6.1
9080 Teratoma, malignant, NOS	7	14.3			7	14.3
9085 Mixed germ cell tumor	9	18.4			9	18.4
9590 Malignant lymphoma, NOS	1	2.0			1	2.0
Total	49	100.0			49	100.0
C63 Other and unspecified male genital organs	No	%	No	%	No	%
8000 Neoplasm, malignant	2	20.0			2	20.0
8070 Squamous cell carcinoma, NOS	5	50.0			5	50.0
8140 Adenocarcinoma, NOS	1	10.0			1	10.0
8850 Liposarcoma, NOS	1	10.0			1	10.0
9591 Malignant lymphoma, non-Hodgkin, NOS	1	10.0			1	10.0
Total	10	100.0			10	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C64	Kidney						
8000	Neoplasm, malignant	9	8.0	5	10.9	14	8.8
8004	Malignant tumor, spindle cell type	1	0.9	0	0.0	1	0.6
8120	Transitional cell carcinoma, NOS	6	5.3	2	4.3	8	5.0
8130	Papillary transitional cell carcinoma	3	2.7	0	0.0	3	1.9
8260	Papillary adenocarcinoma, NOS	4	3.5	2	4.3	6	3.8
8310	Clear cell adenocarcinoma, NOS	13	11.5	5	10.9	18	11.3
8312	Renal cell carcinoma, NOS	66	58.4	24	52.2	90	56.6
8317	Renal cell carcinoma, chromophobe type	0	0.0	1	2.2	1	0.6
8318	Renal cell carcinoma, sarcomatoid	0	0.0	1	2.2	1	0.6
8319	Collecting duct carcinoma	1	0.9	2	4.3	3	1.9
8801	Spindle cell sarcoma	0	0.0	1	2.2	1	0.6
8890	Leiomyosarcoma, NOS	0	0.0	1	2.2	1	0.6
8900	Rhabdomyosarcoma, NOS	1	0.9	0	0.0	1	0.6
8960	Nephroblastoma, NOS	9	8.0	2	4.3	11	6.9
	Total	113	100.0	46	100.0	159	100.0
C65	Renal pelvis	No	%	No	%	No	%
8070	Squamous cell carcinoma, NOS			1	50.0	1	50.0
8120	Transitional cell carcinoma, NOS			1	50.0	1	50.0
	Total			2	100.0	2	100.0
C66	Ureter	No	%	No	%	No	%
8071	Squamous cell carcinoma, keratinizing, NOS	0	0.0	1	100.0	1	33.3
8120	Transitional cell carcinoma, NOS	2	100.0	0	0.0	2	66.7
	Total	2	100.0	1	100.0	3	100.0
C67	Bladder	No	%	No	%	No	%
8000	Neoplasm, malignant	13	5.0	2	3.9	15	4.8
8010	Carcinoma, NOS	3	1.2	0	0.0	3	1.0
8031	Giant cell carcinoma	1	0.4	0	0.0	1	0.3
8050	Papillary carcinoma, NOS	4	1.5	2	3.9	6	1.9
8070	Squamous cell carcinoma, NOS	8	3.1	3	5.9	11	3.5
8120	Transitional cell carcinoma, NOS	171	65.8	26	51.0	197	63.3
8130	Papillary transitional cell carcinoma	50	19.2	10	19.6	60	19.3
8140	Adenocarcinoma, NOS	8	3.1	3	5.9	11	3.5
8211	Tubular adenocarcinoma	0	0.0	1	2.0	1	0.3
8310	Clear cell adenocarcinoma, NOS	0	0.0	1	2.0	1	0.3
8480	Mucinous adenocarcinoma	2	0.8	0	0.0	2	0.6
8900	Rhabdomyosarcoma, NOS	0	0.0	1	2.0	1	0.3
8910	Embryonal rhabdomyosarcoma, NOS	0	0.0	2	3.9	2	0.6
	Total	260	100.0	51	100.0	311	100.0
C68	Other and unspecified urinary organs	No	%	No	%	No	%
8120	Transitional cell carcinoma, NOS	1	100.0			1	100.0
	Total	1	100.0			1	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C69	Eye and adnexa						
8070	Squamous cell carcinoma, NOS	1	3.2	2	10.0	3	5.9
8071	Squamous cell carcinoma, keratinizing, NOS	1	3.2	0	0.0	1	2.0
8083	Basaloid squamous cell carcinoma	1	3.2	0	0.0	1	2.0
8140	Adenocarcinoma, NOS	1	3.2	0	0.0	1	2.0
8200	Adenoid cystic carcinoma	1	3.2	1	5.0	2	3.9
8720	Malignant melanoma, NOS	3	9.7	3	15.0	6	11.8
8900	Rhabdomyosarcoma, NOS	0	0.0	1	5.0	1	2.0
9510	Retinoblastoma, NOS	12	38.7	10	50.0	22	43.1
9511	Retinoblastoma, differentiated	4	12.9	0	0.0	4	7.8
9512	Retinoblastoma, undifferentiated	2	6.5	0	0.0	2	3.9
9591	Malignant lymphoma, non-Hodgkin, NOS	5	16.1	3	15.0	8	15.7
	Total	31	100.0	20	100.0	51	100.0
C70	Meninges						
9240	Mesenchymal chondrosarcoma	1	12.5	0	0.0	1	6.7
9530	Meningioma, malignant	7	87.5	7	100.0	14	93.3
	Total	8	100.0	7	100.0	15	100.0
C71	Brain						
8000	Neoplasm, malignant	4	2.7	4	3.8	8	3.1
9380	Glioma, malignant	29	19.5	22	20.8	51	20.0
9382	Mixed glioma	2	1.3	1	0.9	3	1.2
9390	Choroid plexus carcinoma	1	0.7	0	0.0	1	0.4
9391	Ependymoma, NOS	3	2.0	7	6.6	10	3.9
9392	Ependymoma, anaplastic	0	0.0	1	0.9	1	0.4
9393	Papillary ependymoma	1	0.7	0	0.0	1	0.4
9400	Astrocytoma, NOS	30	20.1	23	21.7	53	20.8
9401	Astrocytoma, anaplastic	5	3.4	4	3.8	9	3.5
9420	Fibrillary astrocytoma	2	1.3	1	0.9	3	1.2
9440	Glioblastoma, NOS	39	26.2	24	22.6	63	24.7
9441	Giant cell glioblastoma	1	0.7	0	0.0	1	0.4
9450	Oligodendroglioma, NOS	11	7.4	6	5.7	17	6.7
9451	Oligodendroglioma, anaplastic	4	2.7	2	1.9	6	2.4
9470	Medulloblastoma, NOS	13	8.7	7	6.6	20	7.8
9500	Neuroblastoma, NOS	2	1.3	0	0.0	2	0.8
9560	Neurilenoma, malignant	0	0.0	1	0.9	1	0.4
9590	Malignant lymphoma, NOS	0	0.0	1	0.9	1	0.4
9591	Malignant lymphoma, non-Hodgkin, NOS	2	1.3	2	1.9	4	1.6
	Total	149	100.0	106	100.0	255	100.0

Site and histology	Male		Female		Total	
	No	%	No	%	No	%
C72 Spinal cord, cranial nerves and other parts of central nervous system						
8000 Neoplasm, malignant	0	0.0	1	8.3	1	6.7
9380 Glioma, malignant	0	0.0	3	25.0	3	20.0
9391 Ependymoma, NOS	1	33.3	4	33.3	5	33.3
9394 Myxopapillary ependymoma	1	33.3	0	0.0	1	6.7
9400 Astrocytoma, NOS	0	0.0	1	8.3	1	6.7
9473 Primitive neuroectodermal tumor, NOS	0	0.0	1	8.3	1	6.7
9500 Neuroblastoma, NOS	1	33.3	0	0.0	1	6.7
9671 Malignant lymphoma, lymphoplasmacytic	0	0.0	1	8.3	1	6.7
9714 Anaplastic large cell lymphoma, T cell and Null cell type	0	0.0	1	8.3	1	6.7
Total	3	100.0	12	100.0	15	100.0
C73 Thyroid gland	No	%	No	%	No	%
8000 Neoplasm, malignant	9	5.0	28	3.4	37	3.7
8010 Carcinoma, NOS	2	1.1	1	0.1	3	0.3
8021 Carcinoma, anaplastic, NOS	14	7.8	18	2.2	32	3.2
8070 Squamous cell carcinoma, NOS	3	1.7	4	0.5	7	0.7
8260 Papillary adenocarcinoma, NOS	94	52.2	409	50.1	503	50.5
8290 Oxyphilic adenocarcinoma	1	0.6	6	0.7	7	0.7
8330 Follicular adenocarcinoma, NOS	19	10.6	135	16.5	154	15.5
8333 Fetal adenocarcinoma	0	0.0	1	0.1	1	0.1
8335 Follicular carcinoma, minimally invasive	1	0.6	12	1.5	13	1.3
8337 Insular carcinoma	0	0.0	2	0.2	2	0.2
8340 Papillary carcinoma, follicular variant	23	12.8	124	15.2	147	14.8
8341 Papillary microcarcinoma	8	4.4	49	6.0	57	5.7
8343 Papillary carcinoma, encapsulated	0	0.0	2	0.2	2	0.2
8344 Papillary carcinoma, columnar cell	0	0.0	1	0.1	1	0.1
8510 Medullary carcinoma, NOS	4	2.2	21	2.6	25	2.5
9590 Malignant lymphoma, NOS	2	1.1	1	0.1	3	0.3
9591 Malignant lymphoma, non-Hodgkin, NOS	0	0.0	2	0.2	2	0.2
Total	180	100.0	816	100.0	996	100.0
C74 Adrenal gland	No	%	No	%	No	%
8000 Neoplasm, malignant	3	18.8	1	12.5	4	16.7
8010 Carcinoma, NOS	1	6.3	1	12.5	2	8.3
8370 Adrenal cortical carcinoma	3	18.8	2	25.0	5	20.8
8700 Pheochromocytoma, malignant	2	12.5	2	25.0	4	16.7
9490 Ganglioneuroblastoma	0	0.0	1	12.5	1	4.2
9500 Neuroblastoma, NOS	7	43.8	1	12.5	8	33.3
Total	16	100.0	8	100.0	24	100.0
C75 Other endocrine glands and related structures	No	%	No	%	No	%
9064 Germinoma	0	0.0	1	50.0	1	20.0
9362 Pineoblastoma	2	66.7	1	50.0	3	60.0
9370 Chordoma, NOS	1	33.3	0	0.0	1	20.0
Total	3	100.0	2	100.0	5	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C76	Other and ill-defined sites						
8000	Neoplasm, malignant	8	30.8	2	6.7	10	17.9
8002	Malignant tumour, small cell type	1	3.8	0	0.0	1	1.8
8003	Malignant tumour, giant cell type	0	0.0	1	3.3	1	1.8
8004	Malignant tumor, spindle cell type	2	7.7	1	3.3	3	5.4
8022	Pleomorphic carcinoma	1	3.8	0	0.0	1	1.8
8051	Verrucous carcinoma, NOS	1	3.8	0	0.0	1	1.8
8070	Squamous cell carcinoma, NOS	4	15.4	4	13.3	8	14.3
8071	Squamous cell carcinoma, keratinizing, NOS	0	0.0	1	3.3	1	1.8
8140	Adenocarcinoma, NOS	1	3.8	3	10.0	4	7.1
8141	Scirrhus adenocarcinoma	0	0.0	1	3.3	1	1.8
8246	Neuroendocrine carcinoma, NOS	0	0.0	3	10.0	3	5.4
8310	Clear cell adenocarcinoma, NOS	0	0.0	1	3.3	1	1.8
8430	Mucoepidermoid carcinoma	1	3.8	0	0.0	1	1.8
8480	Mucinous adenocarcinoma	1	3.8	0	0.0	1	1.8
8720	Malignant melanoma, NOS	1	3.8	0	0.0	1	1.8
9064	Germinoma	0	0.0	1	3.3	1	1.8
9071	Yolk sac tumour	0	0.0	3	10.0	3	5.4
9080	Teratoma, malignant, NOS	1	3.8	2	6.7	3	5.4
9500	Neuroblastoma, NOS	3	11.5	6	20.0	9	16.1
9750	Malignant histiocytosis	1	3.8	0	0.0	1	1.8
9754	Langerhans cell histiocytosis, disseminated	0	0.0	1	3.3	1	1.8
	Total	26	100.0	30	100.0	56	100.0
C77	Lymph nodes						
9590	Malignant lymphoma, NOS	20	5.8	12	5.7	32	5.8
9591	Malignant lymphoma, non-Hodgkin, NOS	178	51.6	111	52.6	289	52.0
9650	Hodgkin lymphoma, NOS	41	11.9	24	11.4	65	11.7
9651	Hodgkin lymphoma, lymphocyte-rich	1	0.3	3	1.4	4	0.7
9652	Hodgkin lymphoma, mixed cellularity, NOS	12	3.5	9	4.3	21	3.8
9659	Hodgkin lymphoma, nodular lymphocyte predominance	2	0.6	0	0.0	2	0.4
9663	Hodgkin lymphoma, nodular sclerosis, NOS	10	2.9	9	4.3	19	3.4
9670	Malignant lymphoma, small B lymphocytic, NOS	6	1.7	3	1.4	9	1.6
9671	Malignant lymphoma, lymphoplasmacytic	2	0.6	0	0.0	2	0.4
9675	Malignant lymphoma, mixed small and large cell, diffuse	2	0.6	0	0.0	2	0.4
9680	Malignant lymphoma, large B-cell, diffuse, NOS	28	8.1	21	10.0	49	8.8
9684	Malignant lymphoma, large B-cell, diffuse, immunoblastic, NOS	1	0.3	1	0.5	2	0.4
9687	Burkitt lymphoma, NOS	1	0.3	0	0.0	1	0.2
9690	Follicular lymphoma, NOS	26	7.5	12	5.7	38	6.8
9691	Follicular lymphoma, grade 2	1	0.3	0	0.0	1	0.2
9699	Marginal zone B-cell lymphoma, NOS	2	0.6	1	0.5	3	0.5
9702	Mature T-cell lymphoma, NOS	3	0.9	2	0.9	5	0.9
9714	Anaplastic large cell lymphoma, T cell and Null cell type	4	1.2	2	0.9	6	1.1
9727	Precursor cell lymphoblastic lymphoma, NOS	5	1.4	1	0.5	6	1.1
	Total	345	100.0	211	100.0	556	100.0

Site and histology		Male		Female		Total	
		No	%	No	%	No	%
C80	Unknown primary site						
8000	Neoplasm, malignant	173	42.8	122	42.2	295	42.6
8010	Carcinoma, NOS	17	4.2	10	3.5	27	3.9
8021	Carcinoma, anaplastic, NOS	1	0.2	0	0.0	1	0.1
8032	Spindle cell carcinoma, NOS	0	0.0	1	0.3	1	0.1
8050	Papillary carcinoma, NOS	1	0.2	1	0.3	2	0.3
8070	Squamous cell carcinoma, NOS	95	23.5	35	12.1	130	18.8
8083	Basaloid squamous cell carcinoma	1	0.2	0	0.0	1	0.1
8140	Adenocarcinoma, NOS	101	25.0	95	32.9	196	28.3
8246	Neuroendocrine carcinoma, NOS	1	0.2	1	0.3	2	0.3
8260	Papillary adenocarcinoma, NOS	4	1.0	12	4.2	16	2.3
8430	Mucoepidermoid carcinoma	0	0.0	1	0.3	1	0.1
8480	Mucinous adenocarcinoma	5	1.2	2	0.7	7	1.0
8481	Mucin-producing adenocarcinoma	1	0.2	0	0.0	1	0.1
8490	Signet ring cell carcinoma	1	0.2	1	0.3	2	0.3
8550	Acinar cell carcinoma	0	0.0	1	0.3	1	0.1
8560	Adenosquamous carcinoma	1	0.2	1	0.3	2	0.3
8720	Malignant melanoma, NOS	1	0.2	2	0.7	3	0.4
8890	Leiomyosarcoma, NOS	0	0.0	1	0.3	1	0.1
8980	Carcinosarcoma, NOS	0	0.0	1	0.3	1	0.1
9064	Germinoma	1	0.2	0	0.0	1	0.1
9500	Neuroblastoma, NOS	0	0.0	1	0.3	1	0.1
9754	Langerhans cell histiocytosis, disseminated	0	0.0	1	0.3	1	0.1
	Total	404	100.0	289	100.0	693	100.0

**Table 14: Lip, oral cavity and pharynx
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	1773	22.6	19.4	2.29
Female	520	5.8	5.2	0.63
Total	2293	13.6	12.0	1.47

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	5	1	6
C00.1 External lower lip	10	8	18
C00.6 Commissure of lip	17	6	23
C00.9 Lip, NOS	12	4	16
C01.9 Base of tongue, NOS	110	13	123
C02.0 Dorsal surface of tongue, NOS	3	3	6
C02.1 Border of tongue	28	5	33
C02.2 Ventral surface of tongue, NOS	1	0	1
C02.3 Anterior 2/3 of tongue, NOS	17	6	23
C02.8 Overlapping lesion of tongue	2	1	3
C02.9 Tongue, NOS	313	69	382
C03.0 Upper gum	19	15	34
C03.1 Lower gum	41	22	63
C03.9 Gum, NOS	32	23	55
C04.0 Anterior floor of mouth	1	0	1
C04.1 Lateral floor of mouth	1	0	1
C04.8 Overlapping lesion of floor of mouth	0	1	1
C04.9 Floor of mouth, NOS	91	11	102
C05.0 Hard palate	20	10	30
C05.1 Soft palate, NOS	66	9	75
C05.2 Uvula	3	0	3
C05.8 Overlapping lesion of palate	0	1	1
C05.9 Palate, NOS	45	11	56
C06.0 Cheek mucosa	283	128	411
C06.1 Vestibule of mouth	4	0	4
C06.2 Retromolar area	35	8	43
C06.8 Overlapping lesion of other/unspecific parts of mouth	27	3	30
C06.9 Mouth, NOS	125	59	184
C09.0 Tonsillar fossa	3	0	3
C09.9 Tonsil, NOS	95	14	109
C10.0 Vallecula	37	6	43
C10.2 Lateral wall of oropharynx	1	0	1
C10.4 Branchial cleft	0	1	1
C10.8 Overlapping lesion of oropharynx	1	0	1
C10.9 Oropharynx, NOS	31	4	35

ICD O code and site	Male	Female	Total
C11.9 Nasopharynx, NOS	40	12	52
C12.9 Pyriform sinus	162	21	183
C13.0 Postcricoid region	17	23	40
C13.1 Aryepiglottic fold	3	0	3
C13.2 Posterior wall of hypopharynx	2	0	2
C13.9 Laryngopharynx, Hypopharynx NOS	7	5	12
C14.0 Pharynx, NOS	53	16	69
C14.8 Overlapping lesion of lip, oral cavity, pharynx	10	1	11
Total	1773	520	2293

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	161	52	213
801-804 Epithelial neoplasms, NOS	15	6	21
805-808 Squamous cell neoplasms	1552	428	1980
814-838 Adenocarcinomas	18	15	33
843 Mucoepidermoid neoplasms	7	10	17
844-849 Cystic, mucinous and serous neoplasms	1	0	1
850-854 Ductal and lobular neoplasms	2	2	4
855 Acinar cell neoplasms	1	1	2
856-857 Complex epithelial neoplasms	2	0	2
868-871 Malignant paragangliomas and glomus tumours	1	0	1
872-879 Malignant nevi and melanomas	2	0	2
880 Soft tissue tumours and sarcomas, NOS	1	0	1
889-892 Myomatous neoplasms	0	1	1
893-899 Complex mixed and stromal neoplasms	0	3	3
912-916 Blood vessel tumours	1	0	1
935-937 Miscellaneous tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	5	2	7
967-969 Mature B-cell lymphomas	2	0	2
973 Plasma cell tumours	1	0	1
Total	1773	520	2293




Figure 07: Age specific rates- Lip, oral cavity and pharynx

**Table 15: Lip and anterior part of oral cavity
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	1087	13.8	11.9	1.47
Female	383	4.2	3.9	0.47
Total	1470	8.7	7.7	0.95

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C00.0 External upper lip	5	1	6
C00.1 External lower lip	10	8	18
C00.6 Commissure of lip	17	6	23
C00.9 Lip, NOS	12	4	16
C02.0 Dorsal surface of tongue, NOS	3	3	6
C02.1 Border of tongue	28	5	33
C02.2 Ventral surface of tongue, NOS	1	0	1
C02.3 Anterior 2/3 of tongue, NOS	17	6	23
C02.8 Overlapping lesion of tongue	2	1	3
C02.9 Tongue, NOS	313	69	382
C03.0 Upper gum	19	15	34
C03.1 Lower gum	41	22	63
C03.9 Gum, NOS	32	23	55
C04.0 Anterior floor of mouth	1	0	1
C04.1 Lateral floor of mouth	1	0	1
C04.8 Overlapping lesion of floor of mouth	0	1	1
C04.9 Floor of mouth, NOS	91	11	102
C05.0 Hard palate	20	10	30
C06.0 Cheek mucosa	283	128	411
C06.1 Vestibule of mouth	4	0	4
C06.2 Retromolar area	35	8	43
C06.8 Overlapping lesion of other/unspecified parts of mouth	27	3	30
C06.9 Mouth, NOS	125	59	184
Total	1087	383	1470

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	91	41	132
801-804 Epithelial neoplasms, NOS	6	2	8
805-808 Squamous cell neoplasms	971	316	1287
814-838 Adenocarcinomas	6	11	17
843 Mucoepidermoid neoplasms	5	7	12
844-849 Cystic, mucinous and serous neoplasms	1	0	1
850-854 Ductal and lobular neoplasms	2	2	4
855 Acinar cell neoplasms	0	1	1
872-879 Malignant nevi and melanomas	2	0	2
889-892 Myomatous neoplasms	0	1	1
893-899 Complex mixed and stromal neoplasms	0	1	1
912-916 Blood vessel tumours	1	0	1
935-937 Miscellaneous tumours	1	0	1
959 Malignant lymphomas, NOS or diffuse	1	1	2
Total	1087	383	1470

**Table 16: Posterior part of oral cavity
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	686	8.7	7.5	0.92
Female	137	1.5	1.4	0.16
Total	823	4.9	4.3	0.52

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C01.9 Base of tongue, NOS	110	13	123
C05.1 Soft palate, NOS	66	9	75
C05.2 Uvula	3	0	3
C05.8 Overlapping lesion of palate	0	1	1
C05.9 Palate, NOS	45	11	56
C09.0 Tonsillar fossa	3	0	3
C09.9 Tonsil, NOS	95	14	109
C10.0 Vallecula	37	6	43
C10.2 Lateral wall of oropharynx	1	0	1
C10.4 Branchial cleft	0	1	1
C10.8 Overlapping lesion of oropharynx	1	0	1
C10.9 Oropharynx, NOS	31	4	35
C11.9 Nasopharynx, NOS	40	12	52
C12.9 Pyriform sinus	162	21	183
C13.0 Postcricoid region	17	23	40
C13.1 Aryepiglottic fold	3	0	3
C13.2 Posterior wall of hypopharynx	2	0	2
C13.9 Laryngopharynx, Hypopharynx NOS	7	5	12
C14.0 Pharynx, NOS	53	16	69
C14.8 Overlapping lesion of lip, oral cavity, pharynx	10	1	11
Total	686	137	823

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	70	11	81
801-804 Epithelial neoplasms, NOS	9	4	13
805-808 Squamous cell neoplasms	581	112	693
814-838 Adenocarcinomas	12	4	16
843 Mucoepidermoid neoplasms	2	3	5
855 Acinar cell neoplasms	1	0	1
856-857 Complex epithelial neoplasms	2	0	2
868-871 Malignant paragangliomas and glomus tumours	1	0	1
880 Soft tissue tumours and sarcomas, NOS	1	0	1
893-899 Complex mixed and stromal neoplasms	0	2	2
959 Malignant lymphomas, NOS or diffuse	4	1	5
967-969 Mature B-cell lymphomas	2	0	2
973 Plasma cell tumours	1	0	1
Total	686	137	823

**Table 17: Trachea, bronchus and lungs
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	875	11.1	10.0	1.33
Female	224	2.5	2.3	0.30
Total	1099	6.5	6.0	0.79

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C33.9 Trachea	1	1	2
C34.0 Main bronchus	18	5	23
C34.1 Upper lobe, lung	12	6	18
C34.2 Middle lobe, lung	1	0	1
C34.3 Lower lobe, lung	5	6	11
C34.9 Lung, NOS	838	206	1044
Total	875	224	1098

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	216	60	276
801-804 Epithelial neoplasms, NOS	243	51	294
805-808 Squamous cell neoplasms	230	28	257
814-838 Adenocarcinomas	179	80	259
843 Mucoepidermoid neoplasms	2	0	2
844-849 Cystic, mucinous and serous neoplasms	3	1	4
856-857 Complex epithelial neoplasms	1	0	1
880 Soft tissue tumours and sarcomas, NOS	1	2	3
889-892 Myomatous neoplasms	0	1	1
965-966 Hodgkin lymphoma	0	1	1
Total	875	224	1098




Figure 08: Age specific rates- Trachea, bronchus and lungs

**Table 18: Larynx
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	393	5.0	4.4	0.59
Female	41	0.5	0.4	0.06
Total	434	2.6	2.3	0.31

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C32.0 Glottis	197	17	214
C32.1 Supraglottis	118	15	133
C32.2 Subglottis	4	0	4
C32.3 Laryngeal cartilage	6	1	7
C32.8 Overlapping lesion of larynx	2	0	2
C32.9 Larynx, NOS	66	8	74
Total	393	41	434

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	28	3	31
801-804 Epithelial neoplasms, NOS	1	2	3
805-808 Squamous cell neoplasms	363	35	398
814-838 Adenocarcinomas	0	1	1
856-857 Complex epithelial neoplasms	1	0	1
Total	393	41	434




Figure 09: Age specific rates- Larynx

**Table 19: Oesophagus
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	656	8.3	7.3	0.92
Female	608	6.7	6.2	0.82
Total	1264	7.5	6.8	0.87

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C15.0 Cervical oesophagus	1	0	1
C15.3 Upper third of oesophagus	14	11	25
C15.4 Middle third of oesophagus	208	241	449
C15.5 Lower third of oesophagus	176	142	318
C15.9 Oesophagus, NOS	257	214	471
Total	656	608	1264

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	62	58	120
801-804 Epithelial neoplasms, NOS	9	7	16
805-808 Squamous cell neoplasms	489	504	993
814-838 Adenocarcinomas	87	33	120
844-849 Cystic, mucinous and serous neoplasms	6	2	8
856-857 Complex epithelial neoplasms	3	2	5
880 Soft tissue tumours and sarcomas, NOS	0	1	1
893-899 Complex mixed and stromal neoplasms	0	1	1
Total	656	608	1264




Figure 10: Age specific rates- Oesophagus

**Table 20: Stomach
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	222	2.8	2.5	0.32
Female	92	1.0	0.9	0.12
Total	314	1.9	1.7	0.21

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C16.0 Cardia, NOS	63	30	93
C16.1 Fundus of stomach	2	1	3
C16.3 Gastric antrum	4	2	6
C16.4 Pylorus	9	8	17
C16.5 Lesser curvature of stomach, NOS	1	0	1
C16.6 Greater curvature of stomach, NOS	1	0	1
C16.9 Stomach, NOS	142	51	193
Total	222	92	314

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	29	3	32
801-804 Epithelial neoplasms, NOS	3	2	5
805-808 Squamous cell neoplasms	15	17	32
814-838 Adenocarcinomas	143	51	194
844-849 Cystic, mucinous and serous neoplasms	25	11	36
889-892 Myomatous neoplasms	1	0	1
893-899 Complex mixed and stromal neoplasms	6	8	14
Total	222	92	314




Figure 11: Age specific rates- Stomach

**Table 21: Colon and rectum
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	521	6.6	5.8	0.71
Female	546	6.0	5.5	0.66
Total	1067	6.3	5.6	0.68

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	25	19	44
C18.1 Appendix	1	2	3
C18.2 Ascending colon	12	14	26
C18.3 Hepatic flexure of colon	3	3	6
C18.4 Transverse colon	13	16	29
C18.5 Splenic flexure of colon	1	2	3
C18.6 Descending colon	4	7	11
C18.7 Sigmoid colon	54	73	127
C18.8 Overlapping lesion of colon	2	1	3
C18.9 Colon, NOS	103	93	196
C19.9 Rectosigmoid junction	32	29	61
C20.9 Rectum, NOS	271	287	558
Total	521	546	1067

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	57	35	92
801-804 Epithelial neoplasms, NOS	2	2	4
805-808 Squamous cell neoplasms	11	8	19
814-838 Adenocarcinomas	407	479	886
844-849 Cystic, mucinous and serous neoplasms	35	18	53
856-857 Complex epithelial neoplasms	2	1	3
872-879 Malignant nevi and melanomas	2	1	3
893-899 Complex mixed and stromal neoplasms	0	1	1
959 Malignant lymphomas, NOS or diffuse	3	1	4
967-969 Mature B-cell lymphomas	2	0	2
Total	521	546	1067




Figure 12: Age specific rates- Colon and rectum

**Table 22: Colon
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	218	2.8	2.4	0.28
Female	230	2.5	2.3	0.29
Total	448	2.7	2.3	0.29

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C18.0 Cecum	25	19	44
C18.1 Appendix	1	2	3
C18.2 Ascending colon	12	14	26
C18.3 Hepatic flexure of colon	3	3	6
C18.4 Transverse colon	13	16	29
C18.5 Splenic flexure of colon	1	2	3
C18.6 Descending colon	4	7	11
C18.7 Sigmoid colon	54	73	127
C18.8 Overlapping lesion of colon	2	1	3
C18.9 Colon, NOS	103	93	196
Total	218	230	448

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	17	16	33
801-804 Epithelial neoplasms, NOS	2	0	2
805-808 Squamous cell neoplasms	2	2	4
814-838 Adenocarcinomas	176	196	372
844-849 Cystic, mucinous and serous neoplasms	15	13	28
856-857 Complex epithelial neoplasms	1	1	2
893-899 Complex mixed and stromal neoplasms	0	1	1
959 Malignant lymphomas, NOS or diffuse	3	1	4
967-969 Mature B-cell lymphomas	2	0	2
Total	218	230	448




Figure 13: Age specific rates- Colon

**Table 23: Rectum, anal canal and anus
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	293	3.7	3.3	0.41
Female	303	3.4	3.0	0.34
Total	596	3.5	3.1	0.37

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C20.9 Rectum, NOS	271	287	558
C21.0 Anus, NOS	15	11	26
C21.1 Anal canal	6	4	10
C21.8 Overlapping lesion rectum, anal canal	1	1	2
Total	293	303	596

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	38	18	56
801-804 Epithelial neoplasms, NOS	0	2	2
805-808 Squamous cell neoplasms	17	14	31
812-813 Transitional cell carcinomas	0	1	1
814-838 Adenocarcinomas	213	262	475
844-849 Cystic, mucinous and serous neoplasms	19	5	24
856-857 Complex epithelial neoplasms	2	0	2
872-879 Malignant nevi and melanomas	4	1	5
Total	293	303	596




Figure 14: Age specific rates- Rectum, anal canal and anus

**Table 24: Breast
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	57	0.7	0.6	0.08
Female	2293	25.4	22.2	2.51
Total	2350	13.9	11.8	1.34

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C50.1 Central portion of breast	0	1	1
C50.2 Upper-inner quadrant of breast	0	1	1
C50.4 Upper-outer quadrant of breast	0	1	1
C50.8 Overlapping lesion of breast	0	1	1
C50.9 Breast, NOS	57	2289	2346
Total	57	2293	2350

CD O code and histology	Male	Female	Total
800 Neoplasms, malignant	5	292	297
801-804 Epithelial neoplasms, NOS	1	20	21
805-808 Squamous cell neoplasms	0	16	16
814-838 Adenocarcinomas	5	23	28
839-842 Adnexal and skin appendage neoplasms	0	2	2
844-849 Cystic, mucinous and serous neoplasms	0	19	19
850-854 Ductal and lobular neoplasms	44	1909	1953
856-857 Complex epithelial neoplasms	1	2	3
880 Soft tissue tumours and sarcomas, NOS	0	2	2
881-883 Fibromatous neoplasms	0	2	2
900-903 Fibroepithelial neoplasms	1	4	5
912-916 Blood vessel tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	0	1	1
Total	57	2293	2350




Figure 15: Age specific rates- Breast

**Table 25: Cervix uteri
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Female	879	9.7	8.7	1.03

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C53.0 Endocervix	1
C53.9 Cervix uteri	878
Total	879

ICD O code and histology	Female
800 Neoplasms, malignant	104
801-804 Epithelial neoplasms, NOS	5
805-808 Squamous cell neoplasms	720
809-811 Basal cell neoplasms	1
814-838 Adenocarcinomas	42
844-849 Cystic, mucinous and serous neoplasms	1
856-857 Complex epithelial neoplasms	5
880 Soft tissue tumours and sarcomas, NOS	1
Total	879




Figure 16: Age specific rates- Cervix uteri

Table 26: Ovary
Incidence data 2009

Group	Number	Percentage	ASR	Cum. Rate
Female	698	7.7	6.8	0.77

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Female
C56.9 Ovary	698
Total	698

ICD O code and histology	Female
800 Neoplasms, malignant	121
801-804 Epithelial neoplasms, NOS	5
805-808 Squamous cell neoplasms	2
812-813 Transitional cell carcinomas	1
814-838 Adenocarcinomas	195
844-849 Cystic, mucinous and serous neoplasms	303
859-867 Specialised gonadal neoplasms	28
881-883 Fibromatous neoplasms	1
893-899 Complex mixed and stromal neoplasms	3
900-903 Fibroepithelial neoplasms	1
906-909 Germ cell neoplasms	38
Total	698




Figure 17: Age specific rates- Ovary

**Table 27: Skin
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	198	2.5	2.1	0.25
Female	119	1.3	1.2	0.15
Total	317	1.9	1.6	0.20

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C44.0 Skin of lip, NOS	3	2	5
C44.1 Eyelid	4	5	9
C44.2 External ear	8	3	11
C44.3 Skin, other & unspecified parts of face	24	15	39
C44.4 Skin of scalp and neck	12	15	27
C44.5 Skin of trunk	21	22	43
C44.6 Skin of upper limb and shoulder	5	4	9
C44.7 Skin of lower limb and hip	68	26	94
C44.8 Overlapping lesion of skin	0	1	1
C44.9 Skin, NOS	53	26	79
Total	198	119	317

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	2	1	3
801-804 Epithelial neoplasms, NOS	6	1	7
805-808 Squamous cell neoplasms	112	48	160
809-811 Basal cell neoplasms	32	31	63
814-838 Adenocarcinomas	3	0	3
839-842 Adnexal and skin appendage neoplasms	5	5	10
843 Mucoepidermoid neoplasms	0	1	1
844-849 Cystic, mucinous and serous neoplasms	0	1	1
872-879 Malignant nevi and melanomas	28	19	47
880 Soft tissue tumours and sarcomas, NOS	1	0	1
881-883 Fibromatous neoplasms	3	3	6
959 Malignant lymphomas, NOS or diffuse	0	4	4
970-971 Mature T-cell and NK-cell lymphomas	6	4	10
975 Neoplasms of histiocytes and accessory lymphoid cells	0	1	1
Total	198	119	317




Figure 18: Age specific rates- Skin

**Table 28: Brain
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	149	1.9	1.5	0.14
Female	106	1.2	1.1	0.10
Total	255	1.5	1.3	0.12

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C71.0 Cerebrum	5	7	12
C71.1 Frontal lobe	19	12	31
C71.2 Temporal lobe	8	5	13
C71.3 Parietal lobe	16	10	26
C71.4 Occipital lobe	3	2	5
C71.5 Ventricle, NOS	1	0	1
C71.6 Cerebellum, NOS	11	6	17
C71.7 Brain stem	12	9	21
C71.8 Overlapping lesion of brain	16	14	30
C71.9 Brain, NOS	58	41	99
Total	149	106	255

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	4	4	8
938-948 Gliomas	141	98	239
949-952 Neuroepitheliomatous neoplasms	2	0	2
954-957 Nerve sheath tumours	0	1	1
959 Malignant lymphomas, NOS or diffuse	2	3	5
Total	149	106	255




Figure 19: Age specific rates- Brain

**Table 29: Thyroid gland
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	180	2.3	1.8	0.19
Female	816	9.0	7.4	0.71
Total	996	5.9	4.7	0.46

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C73.9 Thyroid gland	180	816	996
Total	180	816	996

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	9	28	37
801-804 Epithelial neoplasms, NOS	16	19	35
805-808 Squamous cell neoplasms	3	4	7
814-838 Adenocarcinomas	146	741	887
850-854 Ductal and lobular neoplasms	4	21	25
959 Malignant lymphomas, NOS or diffuse	2	3	5
Total	180	816	996




Figure 20: Age specific rates- Thyroid

**Table 30: Urinary bladder
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	260	3.3	2.9	0.36
Female	51	0.6	0.5	0.07
Total	310	1.8	1.7	0.21

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C67.0 Trigone of bladder	1	0	1
C67.4 Posterior wall of bladder	1	0	1
C67.5 Bladder neck	1	0	1
C67.9 Urinary bladder, NOS	257	51	308
Total	260	51	311

ICD O code and histology	Male	Female	Total
800 Neoplasms, malignant	13	2	15
801-804 Epithelial neoplasms, NOS	4	0	4
805-808 Squamous cell neoplasms	12	5	17
812-813 Transitional cell carcinomas	221	36	257
814-838 Adenocarcinomas	8	5	13
844-849 Cystic, mucinous and serous neoplasms	2	0	2
889-892 Myomatous neoplasms	0	3	3
Total	260	51	311




Figure 21: Age specific rates- Urinary bladder

**Table 31: Hematopoietic and reticuloendothelial system
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	544	6.9	5.8	0.54
Female	481	5.3	4.9	0.49
Total	1025	6.1	5.4	0.51

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male	Female	Total
C42.0 Blood	1	0	1
C42.1 Bone marrow	542	477	1019
C42.2 Spleen	1	3	4
C42.3 Reticuloendothelial system, NOS	0	1	1
Total	544	481	1025

ICD O code and histology	Male	Female	Total
959 Malignant lymphomas, NOS or diffuse	7	5	12
965-966 Hodgkin lymphoma	2	1	3
967-969 Mature B-cell lymphomas	2	2	4
970-971 Mature T-cell and NK-cell lymphomas	1	0	1
972 Precursor cell lymphoblastic lymphoma	1	0	1
973 Plasma cell tumours	111	126	237
976 Immunoproliferative diseases	1	0	1
980 Leukemias, NOS	1	1	2
982-983 Lymphoid leukemias	185	128	313
984-993 Myeloid leukemias	188	184	372
994 Other leukemias	6	2	8
995-996 Chronic myeloproliferative disorders	11	8	19
998 Myelodysplastic syndromes	28	24	52
Total	544	481	1025




Figure 22: Age specific rates- Hematopoietic and reticuloendothelial system

**Table 32: Prostate gland
Incidence data 2009**

Group	Number	Percentage	ASR	Cum. Rate
Male	381	4.8	4.4	0.59

ASR: Age standardized rate per 100,000 world population

Cum. Rate- Cumulative Rate (0-74 years) per 100 population

ICD O code and site	Male
C61.9 Prostate gland	381
Total	381

ICD O code and histology	Male
800 Neoplasms, malignant	106
801-804 Epithelial neoplasms, NOS	1
805-808 Squamous cell neoplasms	3
812-813 Transitional cell carcinomas	1
814-838 Adenocarcinomas	188
844-849 Cystic, mucinous and serous neoplasms	1
850-854 Ductal and lobular neoplasms	2
855 Acinar cell neoplasms	77
880 Soft tissue tumours and sarcomas, NOS	1
967-969 Mature B-cell lymphomas	1
Total	381




Figure 23: Age specific rates- Prostate gland

Staging information of common cancers- 2009

Figures, 24, 25 and 26 give the staging information of the three main cancers namely, breast, cervical and oral cancers. Information on staging was available for 1394 (59.3%) of breast cancers, 518 (58.9%) of cervical cancers and 403 (17.6%) of oral cancers. The percentages computed are out of the cancers with staging information.




Figure 24: Stage at diagnosis- Breast cancer




Figure 25: Stage at diagnosis- Cervical cancer




Figure 26: Stage at diagnosis- Oral cancer

Table 33: Basis of diagnosis of cancer patients 2009

Basis of diagnosis	Frequency	Percent
Diagnosed microscopically		
Histology of primary tumour	14,634	86.7
Cytology/ Haematology	571	3.4
Histology of a metastasis	684	4.1
Subtotal	15,889	94.1
Diagnosed non-microscopically		
Clinical only	28	.2
Clinical Investigation including ultrasound, X-ray, endoscopy etc.	497	2.9
Exploratory surgery	32	.2
Laboratory test	12	.1
Subtotal	569	3.4
Unknown/ Not recorded	430	2.5
Total	16,888	100








**Figure 27: Basis of diagnosis****Figure 28: Basis of diagnosis by major categories**

Table 34: Cancer treatment 2009

Treatment	Frequency	Percentage
Surgery (S)	844	5.0
Radiotherapy (R)	1571	9.3
Chemotherapy (C)	1833	10.9
Hormone (H)	28	0.2
Other -Symptomatic treatment (O)	383	2.3
S + R	1146	6.8
S + C	1104	6.5
S + H	81	0.5
S + O	148	0.9
R + C	1667	9.9
R + H	56	0.3
R + O	372	2.2
C + H	30	0.2
C + O	775	4.6
H + O	32	0.2
S + R + C	918	5.4
S + R + H	168	1.0
S + R + O	176	1.0
S + C + H	128	0.8
S + C + O	205	1.2
S + H + O	36	0.2
R + C + H	53	0.3
R + C + O	461	2.7
R + H + O	27	0.2
C + H + O	4	0.0
S + R + C + H	538	3.2
S + R + C + O	218	1.3
S + C + H + O	33	0.2
S + R + H + O	37	0.2
R + C + H + O	16	0.1
S + R + C + H + O	131	0.8
Treatment unknown	2017	11.9
Total	16888	100.0

Figure 29: Percentage of patients who received different types of treatment



List of References

- Cancer Registry, National Cancer Control Programme (2014), Cancer Incidence Data, Sri Lanka, 2008
- Cancer Registry, National Cancer Control Programme (2013), Cancer Incidence Data, Sri Lanka, 2007
- Cancer Registry, National Cancer Control Programme (2012), Sri Lanka Cancer Incidence Data; Sri Lanka 2006
- Department of Census and Statistics (2012): Number of death by cause, age and sex (2001, 2002, 2003, 2004, 2005, 2006) <http://www.statistics.gov.lk/PopHouSat/VitalStatistics/Tables>
- Department of Census and Statistics; Estimated midyear population by age and sex, 2000-2010
<http://www.statistics.gov.lk/PopHouSat/Mid%20Year%20Population/midyearsex&district.pdf> [01 June 2014]
- Doll, R., Payne, P., Waterhouse, J.A.H. eds (1966). Cancer Incidence in Five Continents, Vol. I. Union Internationale Contre le Cancer, Geneva.
- Fritz, A. Percy, C. Jack, A. Shanmugaratnam, K. Sobin, L. Parkin, D.M. Whelan S. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva
- Glossary of statistical terms; <http://www-dep.iarc.fr/NORDCAN/english/glossary.htm> [01 Dec 2011]
- Indian Cancer Society, Parel, Mumbai, India (2009) Cancer Incidence and Mortality in Greater Mumbai, 2005
- K.S.Chia, A. Seow, H.P. Lee, K. Shanmugaratnam; (2000) Cancer Incidence in Singapore 1993-1997; Singapore Cancer Registry
- Medical Statistics Unit, Ministry of Health, Sri Lanka (2008) Annual Health Statistics, Sri Lanka 2006
- National Cancer Centre, Ministry of Health and Welfare, Republic of Korea (2011) Cancer Facts & Figures 2011
- Segi, M. (1960) Cancer Mortality for Selected Sites in 24 Countries (1950–57). Department of Public Health, Tohoku University of Medicine, Sendai, Japan

Appendix I- Statistical Terminology

Population at risk

It is the part of a population which is susceptible to develop a specific cancer. It is defined on the basis of demographic data, such as place of residence, sex, age group, etc. Years of risk duration are counted in person-years

Incidence

Incidence quantifies the number of new cases of disease that develop in a population of individuals at risk during a specified time interval. Usually it is given as per 100,000 population per year.

Mortality

It is usually expressed as a rate. It is a measure of the number of deaths (in general due to a specific cause) in a specific population, per unit time. Mortality rate is typically expressed in units of deaths per 1000 individuals per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of new cancers or cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. It is usually expressed as an annual rate per 100,000 persons at risk.

Crude incidence rate

= Total number of cases in the year/ Total midyear population at risk

Crude death rate

= Total number of deaths in the year/ Total midyear population at risk

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five-year age categories are used (highest group 75+).

Age –specific incidence rate

= Number of cases in the five-year age group/ population at risk in the corresponding age group

Age –specific death rate

= Number of deaths in the five-year age group/ population at risk in the corresponding age group

ASR (age-standardised rate)

Standardised rates are statistically constructed summary rates that account for the difference between populations. An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardisation is necessary when comparing several populations that differ with respect to age because age has such a powerful influence on the risk of cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the standard population. In this publication 'World Population' was taken as the standard population.

National Cancer Control Programme
555, Elvitigala Mawatha
Colombo 5
Sri Lanka



9 789550 505746